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Executive summary 
 
Project objective 
The main objective of the EQUS project, as set out in the call for tenders, is to collect 
existing national and international information on quality standards and benchmarks in 
drug demand reduction, to set up an inventory of these standards and benchmarks, and 
to extract from the inventory lists of minimum quality standards to be submitted to a 
range of relevant stakeholders for approval. The result is intended to facilitate a quality 
awareness and improvement process throughout the EU Member States.   
 
The various elements of the project are summarised as follows: 
 
a. To describe the background and the tasks of the project 
b. To describe the methods used for developing the inventories  
c. To describe the consensus building process fort the final results of the project 
d. To outline problems and perspectives fort the implementation of the proposed 
minimum quality standards at European level 
e. A summary of project results 
 
Background 
 
All approaches to drug demand reduction have expanded and diversified 
considerably during the last two decades. New intervention types are developed and 
evaluated, new settings are included in the treatment and prevention networks, 
special target populations have gained more attention. A main focus was and is on 
capacity building in order to reach out to those in need of interventions and to 
increase coverage of prevention, treatment and harm reduction services. However, 
services must be of good quality in order to be effective. The quest for quality 
standards is essential. Using available knowledge  from research evidence  on «what 
works», overriding discriminatory and negative attitudes towards people with 
substance abuse problems, respecting human rights and medical ethics are all part of 
quality. But while research evidence on efficacy and effectiveness of interventions is 
growing and can be accessed through reviews and guidelines, a consensus on quality 
standards still needs to build up.  
 
The European Action Plan on Drugs 2009-2012 agreed by the EU member 
governments therefore asked the European Commission to develop an EU consensus 
of minimum quality standards in the field drug demand reduction. To underpin its 
work, the European Commission (DG Justice) contracted the Swiss Research 
Institute for Public Health and Addiction (ISGF) to carry out a study to collect 
information on quality standards and benchmarks in Member States and to propose 
options for minimum quality standards for drug demand reduction.  
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The options proposed by the ISGF consist of the three lists of proposed minimum 
quality standards in drug prevention, treatment/rehabilitation and harm reduction, and 
of reflections and recommendations for the implementation of those standards. 
 
The project contract did not envisage new research to develop best-evidence or best-
practices in those areas where this is not already available. 
 
The list proposed by the ISGF describes quality standards at the intervention level 
(mainly of interest for professionals working in prevention, treatment and harm 
reduction services), at the service level (mainly of interest for service directors) and at 
the system level (mainly of interest for policy planners and managers). 
 
This project is understood as the start of a longer term consultation process with 
stakeholders to build a consensus on minimum quality standards for drug demand 
reduction interventions and services which EU Member States have or are planning to 
implement in their own country.  
 
It is important to note that the project gives no information about the benefits of any 
specific service or intervention in the field of drug demand reduction, or about the 
acceptability of implementing those, but only on the acceptability of minimum quality 
standards in case a specific intervention or service is already implemented or will be 
implemented. 
 
 
The tasks of the project 
 
The tasks were presented in the call for tenders and formed the core of the work plan 
of the project. They are: 
 
- To establish an expert group consisting of Commission, EU and international 
experts with ample experience in the implementation and evaluation of demand 
reduction interventions as well as the formulation and application of quality 
standards for interventions and services in this field.   
- To identify, map and review existing quality standards and benchmarks in drug 
prevention, early detection and early intervention, treatment, harm reduction and 
social rehabilitation and reintegration in EU Member States and/ or at European 
and/ or international level, and to provide a gap analysis for those areas where 
these do not exist so far. 
- To propose and help set up a consultation and consensus building mechanism for 
relevant stakeholders at EU leve.l 
- To develop a design for a framework of quality standards and benchmarks, 
identifying the structure, key aspects, type and level of specification/ detail of 
these standards and benchmarks. This design should also reflect on potential risks, 
uncertainties and other factors that may be of importance in the design of quality 
standards at EU level. 
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- To apply this framework by populating it with options and suggestions for quality 
standards and benchmarks and which can form the basis for discussions between 
experts and policy makers in this area. 
- To prepare a set of working papers on each of the relevant areas, which are to be 
prepared before and discussed during two seminars for experts to be organised in 
cooperation with the European Commission in the course of 2010. 
- To draft – on the basis of the feedback received – an overall working document for 
a European Conference for policy makers, researchers and professionals to be 
organised in 2011. 
- To prepare for the Commission a final report consisting of options on EU 
minimum quality standards and benchmarks in the field of drug demand reduction. 
 
Methods used for developing the inventories  
 
In the fields of treatment/rehabilitation and harm reduction, the collection of relevant 
documents for setting up the inventory of existing quality standards and benchmarks 
(task 2) was organised in collaboration with a range of experts (task 1) as project 
partners. They received detailed instructions for the selection of relevant documents 
and for transmitting structured information from these via on-line templates to a 
central electronic file at the coordinating institute. 
 
In the field of prevention, another European project carried out by John Moores 
University Liverpool in collaboration with EU partners had already performed a 
search of relevant documents and extracted quality standards. 
 
The consensus building process   
 
Treatment/rehabilitation and harm reduction: On the basis of the inventory, a set of  
quality standards (24 for treatment/rehabilitation, 25 for harm reduction) was extracted 
and submitted to the collaborating project partners in an expert seminar and then to 
514 stakeholders from all Member States in two on-line surveys. The participant 
stakeholders rated the proposed standards as already implemented, acceptable without 
probblems, acceptable with problems or unacceptable. The ratings resulted in separate 
lists of minimum quality standards with high consensus of acceptability (<80% of 
acceptance), with moderate consensus (50-80% of acceptability) and low consensus 
(>50% of acceptability).  
 
The stakeholders participating in the European Conference on the EQUS project 
(Brussels, June 15-17 2011) discussed these lists and some modifications. The 
resulting final list of proposed minimum quality standards and benchmarks is added at 
the end of  this executive summary. 
 
Prevention: A consensus building process including Delphi surveys and focus groups 
was part of the above mentioned project.  
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Problems and perspectives fort the implementation oft the proposed minimum 
quality standards at European level. 
 
The questionnaire for the on-line surveys included questions about the expected 
implementation problems (political, professional, legal, ethical, financial problems). 
The results were presented at the European Conference, and examples of establishing 
good quality systems at national level were explained. The debate pointed out a 
general consensus that there is no major opposition against implementing minimum 
standards and benchmarks, but that further steps at national and regional level must 
follow to bring the consensus building process and the implementation of minimum 
standards further ahead. 
 
A summary of project results 
 
The work plan could be realised step by step as it was proposed in the tender. The 
highly qualified expert group contributed, in addition to collecting and screening the 
relevant documents, by making some methodological adjustments and by participating 
actively in the consensus building process. A well documented list of proposed 
minimum quality standards resulted; problems and models of implementation could be 
explored and recommendations for further steps presented. 
     
The final list of experts collaborating in the project (task 1) contains overall 52 experts 
from 25 countries. 
 
The inventory (task 2) contains 350 documents (260 for treatment/rehabilitation, 90 
for harm reduction) from 27 countries 
 
The provisional list of quality standards and benchmarks, extracted from the 
inventory, contains 78 standards (prevention 29, treatment/rehabilitation 24, harm 
reduction 25) 
 
The two on-line surveys of stakeholders were answered by 241 professionals (47% of 
514 invited stakeholders) from 20 countries 
 
128 stakeholders from 34 countries participated in the European Conference on the 
EQUS project 
 
The final list of proposed minimum standards contains 33 standards for prevention, 22 
standards for treatment/rehabilitation and 16 standards for harm reduction ; no 
benchmarks are identified. 
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Next steps 
 
The list of proposed minimum quality standards are recommendations addressed to the 
European Commission to underpin its work on a proposal for an EU consensus on 
minimum quality standards, now planned for 2013.  
 
European level minimum quality standards will need  to add value to what exists in the 
EU member states and take account of different health systems and capacities across 
Member States.   
 
Political choices still have to be made and further research carried out to strengthen 
available the evidence base as described in the gap analysis.  
 
It is highly recommended to continue the consensus building process with 
stakeholders, in parallel to the political decision-making process, to promote a 
common understanding of the need and objectives of the proposed quality standards in 
the field of drug demand reduction. 
 
As an incentive and to encourage the consensus building process at national and EU 
level, the European Commission has confirmed that will propose EU funding  for such 
initiatives under its Drug Prevention and Information Programme 2012 as well as 
funding for further research to support the evidence base of the quality standards. 
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EQUS List of Minimal Quality Standards 
(comments and exceptions are inserted in chapter 6) 
 
a. Prevention standards  
 
Prevention: Structural Standards of Services 
 
P1 Ethical principles: adherence to ethical principles (e.g. service must protect 
participants’ rights, provide services/interventions that have clear benefits for 
participants, must not provide a service/intervention where evidence shows that it 
could harm participants (e.g. increase drug use, stigmatise participants)) 
 
P2 Policy and legislation: reference to drug-related policy and legislation as required for 
the implementation of the service/intervention 
 
P3 Routine cooperation with other agencies: the organisation cooperates with other 
agencies and institutions in correspondence with the multi-service nature of drug 
prevention (e.g. health and social services, criminal justice services, educational 
services) 
 
P4 Financial requirements: a clear and realistic cost estimate is provided; available 
funding streams are sufficient to cover costs 
 
P5 Internal resources and capacities: sufficiently available for implementation (e.g. 
human, technological, financial resources) 
 
P6 Staff composition: transdisciplinarity and qualifications of staff are appropriate for the 
service (e.g. type of roles, number of staff, level of education) 
 
P7 Staff support: staff members are supported in their work as appropriate 
 
Prevention: Process Standards of Services/Interventions 
 
P8 Ethical standards: adherence to ethical standards (e.g. intervention is only carried out 
if there is a need for it, procedures in place to ensure informed consent, confidentiality, 
protect safety of participants and staff members, information about drugs and related 
behaviours is accurate where it is provided) 
 
P9 Assessment procedures: detailed and diverse information on drug use in the 
community/target population/environment of interest has to be collected through 
primary or secondary study (e.g. types of drugs used, drug use rates and trends) 
 
P10 Assessment procedures: target population’s culture (1. relation to drug use, 2. relation 
to the service/intervention activities) has to be assessed 
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P11 Assessment procedures: other relevant characteristics of the community/target 
population/environment have to be assessed (e.g. cognitions, attitudes, risk behaviours, 
criminality, social status, drug availability) 
 
P12 Assessment procedures: target population and community readiness for the 
service/intervention has to be assessed (e.g. sources of opposition or support) 
 
P13 Assessment procedures: gaps in current service provision have to be assessed 
 
P14 Stakeholder involvement: all stakeholders relevant to the service/intervention are 
involved in its development and implementation as required (e.g. target population, 
other agencies) 
 
P15 Sustainability: long-term strategy for drug prevention or wider health promotion (all 
activities form part of the long-term strategy) 
 
P16 Goal definition: service/intervention goals are specific, realistic and informed by 
assessment procedures (e.g. what types of drug use or behaviours are targeted) 
 
P17 Service/intervention design: the service/intervention is based on a scientifically 
derived understanding (theoretical models) of drug-related behaviours and behavioural 
change  
 
P18 Service/intervention design: the service/intervention is evidence-based (it is based 
upon the findings of novel or existing literature reviews on scientific evidence of 
effectiveness, or professional experience where reviews are not available) 
 
P19 Service/intervention design: services/interventions are tailored according to individual 
and population characteristics (e.g. language, activities, messages, timing, number of 
participants) 
 
P20 Service/intervention design: criteria for end of the service/intervention are defined 
(e.g. goals achieved, mandatory number of sessions completed, number of participants 
reached, duration of the intervention) 
 
P21 Service/intervention design: service/intervention activities are feasible and internally 
consistent (e.g. activities are linked to objectives, target population is chosen in line 
with needs assessment, target population can be reached, setting is suitable for good 
functioning) 
 
P22 Adaptation: existing interventions (e.g. manualised programmes, service models 
implemented elsewhere) are adapted considering the differences between the original 
and the actual circumstances (e.g. target population characteristics) 
 
P23 Staff training and development: those delivering the service/intervention (e.g. staff 
members, teachers, parents, former drug users) have the competencies which are 
required for a successful implementation  
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P24 Recruitment: participants or participating units (e.g. schools, communities) are drawn 
from the defined target population 
 
P25 Implementation: a systematic project plan exists in writing (e.g. including main 
service/intervention elements and procedures, risk assessment and contingency plans) 
 
P26 Implementation: the implementation is monitored and necessary adjustments identified 
(e.g. reviewing preliminary outcome and process data, project plan, resources) 
 
P27 Implementation: the service/intervention is implemented according to the project plan 
and adjusted in line with the monitoring findings  
 
P28 Process evaluation: the implementation is documented and explained (failures and 
deviations from the original plan, target population involvement, activities, 
service/intervention delivery, use of financial, human, and material resources) 
 
P29 Dissemination: a written and clear description of the service/intervention is made (at 
least partly) available to relevant groups (e.g. participants) before and/or during the 
service/intervention 
 
P30 Dissemination: information about the service/intervention is disseminated in an 
appropriate format (e.g. evidence briefings, report to funders, feedback to participants) 
at the end of the service/intervention 
 
Prevention: Outcome Standards at the System Level 
 
P31 Goal of prevention: reduced drug use (prevention must be aimed at abstention, delayed 
drug use, reduced drug use, and/or prevention of dependence) 
 
P32 Evaluation: an appropriate evaluation is carried out as part of the service/intervention 
(e.g. outcome evaluation, process evaluation) 
 
P33 Evaluation: the service/intervention is continued on the basis of evidence provided by 
monitoring or evaluation 
 
 
b. Treatment/rehabilitation standards 
  
Treatment/rehabilitation: Structural Standards of Services 
 
TR1 Accessibility: location (service can easily be reached by public transport) 
 
TR2 Physical environment: adequate spacing for the activities in the service (e.g. service 
has separate rooms for individual counselling) 
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TR3 Physical environment: safety (service is equipped for emergencies like e.g. 
management of overdose, fire or aggression on the premises) 
 
TR4 Indication criteria: diagnosis (treatment indication is always made on  the basis of a 
diagnosis) 
 
TR5 Staff education: basic education (e.g. at least half of staff has a diploma in medicine, 
nursing, social work, or psychology) 
 
TR6 Staff composition: transdisciplinarity (e.g. service employs a multidisciplinary team 
composed of at least 3 professions) 
 
Treatment/rehabilitation: Process Standards at the Service Level 
 
TRs7 Assessment procedures: substance use history, diagnosis and treatment history have to 
be assessed 
 
TRs8 Assessment procedures: somatic status and social status have to be assessed 
 
TRs9 Assessment procedures: psychiatric status has to be assessed 
 
TRs10 Individualised treatment planning (treatment plans are tailored individually to the 
needs of the patient) 
 
TRs11 Informed consent (patients must receive information on available treatment options 
and agree with a proposed regime or plan or a change of plan before starting 
treatment)  
 
TRs12 Written client records (assessment results, intervention plan, interventions, expected 
changes and unexpected events are documented complete and up to date for each 
patient in a patient record) 
 
TRs13 Confidentiality of client data (patient records are confidential and exclusively 
accessible to staff involved in a patient’s treatment or regime) 
 
TRs14 Routine cooperation with other agencies (whenever a service is not equipped to deal 
with all needs of a given patient, an appropriate other service is at hand for referral) 
 
TRs15 Continued staff training (staff is regularly updated on relevant new knowledge in their 
field of action) 
 
Treatment/rehabilitation: Process Standards of Interventions 
 
TRi7 Assessment procedures: substance use history, diagnosis and treatment history have to 
be assessed 
 
TRi8 Assessment procedures: somatic status and social status have to be assessed 
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TRi9 Assessment procedures: psychiatric status has to be assessed 
 
TRi10 Individualised treatment planning (treatment plans are tailored individually to the 
needs of the patient) 
 
TRi11 Informed consent (patients must receive information on available treatment options 
and agree with a proposed regime or plan or changes of plan before starting treatment) 
 
TRi12 Written client records (assessment results, intervention plan, interventions, expected 
changes and unexpected events are documented complete and up to date for each 
patient in a patient record) 
 
TRi13 Confidentiality of client data (patient records are confidential and exclusively 
accessible to staff involved in a patient’s treatment or regime) 
 
TRi14 Routine cooperation with other agencies (whenever a service is not equipped to deal 
with all needs of a given patient, an appropriate other service is at hand to referral) 
 
TRi15 Continued staff training (staff is regularly updated on relevant new knowledge in their 
field of action) 
 
Treatment/rehabilitation: Outcome Standards at the System Level 
 
TR16 Goal: health stabilisation/improvement (treatment must aim at improvements or 
stabilisation of health) 
 
TR17 Goal: social stabilization/integration (treatment must aim at improvements of social 
stabilisation or integration) 
 
TR18 Goal: reduced substance use (treatment must aim at a reduction of substance use e.g. 
helping the client/patient to reduce the use or to abstain from illegal or nonprescribed 
psychotropic substances) 
 
TR19 Utilisation monitoring (services must report periodically the occupancy of treatment 
slots or beds) 
 
TR20 Discharge monitoring (e.g. ratio of regular / irregular discharges and retention rates 
have to be monitored periodically) 
 
TR21 Internal evaluation (services must regularly perform an internal evaluation of their 
activities and outcomes) 
 
TR22 External evaluation (services must regularly allow an evaluation of their activities and 
outcomes by an independent external evaluator) 
 
 
14 
 
c.  Harm reduction standards 
 
Harm Reduction: Structural Standards of Interventions  
 
HR1 Accessibility: location and opening hours (services have to match the needs of their 
clients; costs should never be a barrier to a service) 
 
HR2 Staff qualification: minimal qualification (staff has to be qualified and the staff 
qualification has to be made transparent, e.g. amongst two trained peers involved in 
the service, two have a diploma in social work and further two in nursing) 
 
HR3 Indication criteria: age limits (1. Services have to be age appropriate and staff has to 
be trained to meet age appropriate clients needs, 2. There should be no age limits in 
harm reduction services) 
 
Harm Reduction: Process Standards of Interventions  
 
HR4 Assessment procedures: risk behaviour assessment (client’s/patient’s risk behaviour is 
assessed) 
 
HR5 Assessment procedures: complete needs assessment and priorisation (e.g. 1. Harm 
reduction of intravenous drug use and, 2. Reduction of used syringes in public spaces 
etc.) 
 
HR6 Assessment procedures: client/patient status (the client’s/patient’s health status is 
assessed) 
 
HR7 Informed consent (Clients/patients must receive information on available service 
options and agree with a proposed regime or plan before starting an intervention. 
Interventions should not be based on written informed consent, but rather on a 
transparently information about all the offers by a service.) 
 
HR8 Confidentiality of client data (client/patient records are confidential and exclusively 
accessible to staff involved in a client’s/patient’s intervention or regime) 
 
HR9 Individualised treatment planning (intervention regime and intervention plans, if 
applicable, are tailored individually to the needs of the client/patient) 
 
HR10 Routine cooperation with other agencies (whenever a service is not equipped to deal 
with all needs of a given client/patient, an appropriate other service is at hand for 
referral) 
 
HR11 Continued staff training (staff is regularly updated on relevant new knowledge in their 
field of action) 
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HR12 Neighbourhood/community consultation (avoiding nuisance and conflict with other 
people around the service) 
 
Harm Reduction: Outcome Standards at the System Level 
 
HR13 Goal: reduced risk behaviour (reducing unsafe injections, unsafe drug use and 
unprotected sex) 
 
HR14 Goal: referrals (treatment services must be prepared to refer clients/patients to other 
health/social/treatment/legal services if needed and agreed) 
 
HR15 Internal evaluation (services must regularly perform an internal evaluation of their 
activities and outcomes) 
 
HR16 External evaluation (services must regularly allow an evaluation of their activities and 
outcomes by an independent external evaluator) 
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1. Introduction 
 
Drug demand reduction approaches have evolved over more than 40 years, since the 
use of illicit drug use started in the late 1960ties. During this period, major changes in 
the concepts and methods occurred. Prevention developed into a highly professional 
activity, including health education as well as substance specific approaches in various 
settings (schools, workplace, recreational settings) and for various target populations 
(general public, populations at risk, people engaged in hazardous or harmful use). 
Treatment approaches have diversified, for specific substances, specific target groups, 
in a range of specialised settings and in primary health and social care. Harm reduction 
started as a reaction to the Aids epidemic, aiming at the protection of injectors against 
blood borne infectious diseases. In general, objectives moved from a primarily 
abstinence-oriented focus to an integrated view of offering appropriate interventions 
tailored to the needs of users, from emergency interventions and harm reduction 
measures for chronic users, to motivational interventions for those in need of 
behavioural change, to structured therapy for those in search of abstinence. 
 
An inventory of available treatments for drug abuse and drug dependence in the 
European Union includes pharmacological and psychosocial approaches (Haasen 
2008). Pharmacological methods are used in detoxification therapy, in opioid 
substitution therapy (mainly using Methadone and Buprenorphine as maintenance 
medications replacing illegal opioids) and in relapse prevention (mainly using 
Acamprosate and Naltrexone, an opiate antagonist, as medications in a maintenance 
regime). Psychosocial methods include cognitive behavioural therapy (e.g. 
contingency management and community reinforcement (especially for non-opioid 
abuse and dependence) and family therapy (especially for adolescent drug abuse); 
motivational enhancement methods are used to increase willingness to engage in 
treatment or as an adjunct during treatment. 
 
An inventory of available harm reduction approaches and services includes needle and 
syringe exchange programmes, low threshold consultation and treatment services, 
drug consumption facilities and activities in recreational settings (Rhodes & Hedrich 
2010). Data are available on effects and side-effects, on experience and comments 
from various stakeholders and on the various ethical aspects. 
 
Diversification and accumulated experience made it necessary to systematise the 
know-how in these fields of action. Evaluation research was increasingly encouraged 
and funded, with an aim to provide guidance on “what works”, and an increasing 
number of reviews and guidelines helped professionals to keep themselves informed 
on evidence-based recommendations for their work. Evaluation methodology, review 
methodology and guidelines how to produce guidelines, were set up in order to guide 
this development. Cochrane and Campbell reviews are setting the standards for 
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reviewing outcome studies1, World Health Organisation has pioneered the 
development of international evidence-based treatment guidelines2. 
 
In recent years, the debate on the quality of prevention, treatment and harm reduction 
systems has gained momentum. Standards can provide an important quality 
management tool for improving the effectiveness and efficiency of drug prevention 
programmes, drug treatment interventions and harm reduction services.  A world-wide 
project of UNODC, designed to upscale evidence-based treatment facilities in 20 
countries and to support the respective governments in developing national networks 
of community-based drug treatment centres and social services providers, has recently 
engaged in setting up standards for quality of care (UNODC 2011).  
 
Quality as an issue in drug demand reduction activities was at first mainly envisaged 
in attempts to formulate good practice or best practice in prevention, treatment and 
harm reduction. As stated in the EU action plan on drugs 2005-2008, “effective 
dissemination of evaluated best practices” should be made available. The Directorate 
of Health and Consumer Affairs SANCO launched in 2006 a European project on 
models of good practice in treatment, and EMCDDA has collected relevant 
information from national Focal Points. The results are accessible via the science-
based Best Practice Portal.3 
 
In this context, EMCDDA has defined quality standards as « generally accepted 
principles or sets of rules for the best/most appropriate way to implement an 
intervention. Frequently they refer to structural (formal) aspects of quality assurance, 
such as environment and staff composition. However they may also refer to process 
aspects, such as adequacy of content, process of the intervention or evaluation 
processes ».4  The Best Practice Portal of the European Monitoring Centre for Drugs 
and Drug Addiction became an increasingly important resource for professionals, 
policymakers and researchers in the drugs field.  The portal also provides an overview 
of the available quality standards and guidelines in the European Union (EU) Member 
States. 
 
Improving the quality and effectiveness of prevention, treatment, harm reduction, 
rehabilitation and social reintegration is a priority under the EU Drugs Strategy 2005-
2012.  
                                                 
1 For Cochrane reviews see www.2.cochrane.org/reviews; for Campbell see 
www.campbellcollaboration.org/library 
2 Best example are the International Guidelines for psychosocially assisted pharmacological treatments 
of opioid dependence », Geneva 2008. They also include a list of minimal requirements. Another 
document jointly published by the United Nations Office on Drugs and Crime UNODC and World 
Health Organisation are the « Principles of drug dependence treatment, a discussion paper », Vienna 
and Geneva 2008.It summarises the state of knowledge on drug dependence treatment, but without 
indicating minimum quality standards. 
3 http://www.emcdda.europa.eu/best-practice 
4 www.emcdda.europa.eu/best-practice/standards 
18 
 
By adopting the Strategy5, the EU Member States agreed the following goal: 
 
"A measurable reduction of the use of drugs, of dependence and drug-related 
health and social risks through the development and improvement of an 
effective and integrated knowledge-based demand reduction system including 
prevention, early detection, treatment, harm reduction, rehabilitation and 
social reintegration measures within the EU Member States".  
 
To implement this important goal, the EU Member States agreed, in the EU drugs 
action plan 2005-2008, the development of a wide range of drug demand reduction 
interventions covering prevention, treatment, harm reduction, rehabilitation and social 
reintegration. They also called for the further improvement of the quality, 
accessibility, effectiveness and coverage of drug interventions and services. 
 
In 2008 the European Commission carried out an evaluation of the measures taken by 
the EU countries towards meeting the aims of the EU drugs action plan 2005-2008 and 
concluded that6: 
 
¾ Member States have invested in universal, selective and indicated prevention 
programmes across the board, but the evidence base underpinning these 
programmes is still weak and they are seldom evaluated.  
 
¾ Only a handful of Member States have introduced general quality guidelines 
for prevention. 
 
¾ An increasing number of Member States have also developed quality 
guidelines for treatment programmes, but the level of application is still 
unclear. (…)".  
 
¾ "The availability of standardised information and data on the social 
consequences of drug use is very limited. This also includes information on the 
efforts made by Member States to rehabilitate and reintegrate (problematic) 
drug users in society." 
 
The Commission’s evaluation report therefore recommended that "greater attention 
should be paid to the development and actual implementation of quality guidelines and 
benchmarks for effective interventions in the field of drug demand reduction"7.  
 
This recommendation was subsequently translated into the EU Drugs Action Plan 
2009-20128 through the adoption of a specific action that aimed: 
 
                                                 
5 15074/04, CORDROGUE 77, 22.11.2004, section 22; 
6 Final Evaluation of the EU drugs action plan 2005-2008, SEC (2008) 2456, 18.9.2008; 
7 Ibid, § 6.2.2, p. 69; 
8 OJ 326, 20.12.2008, Action 19; 
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"To develop an EU consensus on minimum quality standards and benchmarks 
for prevention, treatment, harm reduction and rehabilitation interventions and 
services, taking into account needs of specific groups and the work done at 
national and international level".  
 
The EU Drugs Action Plan requests that by 2012 the European Commission tables a 
proposal to the Council (made up of the 27 EU government's representatives) for an 
EU Consensus on minimum quality standards and benchmarks in drug demand 
reduction. 
With the entry into force of the Lisbon Treaty, the scope for EU cooperation and 
coordination towards improving public health was strengthened9 and provides a legal 
basis for the Commission, in close contact with the Member States, to take any useful 
initiative to – inter alia – promote such coordination, in particular initiatives aiming at 
the establishment of guidelines and indicators, the organisation and exchange of best-
practice, and the preparation of the necessary elements for periodic monitoring and 
evaluation.  
 
The development of a set of minimum quality standards and benchmarks at EU level is 
an ambitious challenge given the national differences in terms of drug use and drug 
problems as well as the differences in the organisation of public health care systems, 
cultural and socio-economic factors. Nevertheless, there is considerable scope to 
improve the quality of interventions, programmes and services in the drugs field. 
Sharing experience and learning from best practice has a valuable role to play at the 
EU level.  
 
Therefore, the European Commission (Directorate General for Justice) launched a 
study in May 2010 to help prepare its proposal for a European consensus on minimum 
quality standards. 
 
In the specifications to the tender, the final task is defined: 
 
(7) To prepare for the Commission a final report consisting of options on EU 
minimum quality standards and benchmarks in the field of drug demand 
reduction. 
 
The options consist of the three lists of proposed minimum quality standards in drug 
prevention, treatment/rehabilitation and harm reduction, and of reflections and 
recommendations for the implementation of those standards. 
 
The project contract did not ask for new research designed to develop best-evidence or 
best-practices in those areas where this is not already available.  
 
This project is intended as the start of a longer term consultation process with 
stakeholders to build a consensus on minimum quality standards for drug demand 
reduction interventions and services which EU Member States have or are planning to 
                                                 
9 OJ C 115, 9.5.2008, Art. 168 (1),(2),(6) 
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implement in their own country. It is important to note that the project gives no 
information about the benefits of any specific service or intervention in the field of 
drug demand reduction, or about the acceptability of implementing those, but only on 
the acceptability of minimum quality standards in case a specific intervention or 
service is already implemented or will be implemented. 
 
This report will, in addition to the options, summarise the background of the project 
and how the tasks of the tender have been dealt with, including methodology, in order 
to provide the basis on which the options have been built. 
 
The target audiences for minimum quality standards are diverse: professionals 
performing interventions, service directors and managers responsible for the 
functioning of their institutions and staff, and health authorities, planners and policy 
makers who are mainly concerned with the drug demand reduction activities at the 
system and network level. In addition, all users - patients and their families as well as 
professionals referring patients to services – have an interest in knowing the quality 
requirements.  Not all standards are of equal interest for these audiences; structural 
standards are especially relevant for service directors, process standards for service 
directors and professional staff, outcome and economic standards and benchmarks for 
authorities and policy makers. For user groups, especially the structural and process 
standards are of interest. 
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2. Mandate and project outline 
 
a. Mandate 
The European Commission (Directorate General for Justice) launched a study in May 
2010 to help prepare its proposal for a European consensus on minimum quality 
standards. 
 
The study on minimum European Quality Standards (EQUS) in the field of drug 
demand reduction is carried out by the Research Institute for Public Health and 
Addiction, Zurich University, in cooperation with the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) and in contact with the World Health 
Organisation (WHO).  
 
The scientific work within the project is supported by a European and international 
group of experts with significant experience in the implementation and evaluation of 
demand reduction interventions10. The EQUS group includes experts from across the 
EU Member States as well as Norway, Switzerland, USA, Canada and Australia. The 
role of the experts is to review the inventories of quality standards and the list of 
minimum quality standards proposed.  
 
In summary, the EQUS project consists of the following tasks11:  
 
¾ To identify, map and review existing quality standards and benchmarks in drug 
prevention, early detection and early intervention, treatment, harm reduction 
and social rehabilitation and reintegration in EU Member States and/ or at 
European and/ or international level, and to provide a gap analysis for those 
areas where these do not exist so far. 
 
¾ To set up a consultation and consensus building mechanism for relevant 
stakeholders at EU level, involving scientific experts, professionals/ 
practitioners, policy makers and other important stakeholders, including 
organised representatives of relevant target groups of interventions. 
 
¾ To develop a design for a framework of quality standards and benchmarks, 
identifying the structure, key aspects, type and level of specification/ detail of 
these standards and benchmarks.  
 
¾  This design should also reflect on potential risks, uncertainties and other 
factors that may be of importance in the design of quality standards at EU 
level. 
 
                                                 
10  See chapter 4a and Annex 1 for list of  EQUS experts 
11 From specifications in the call for tenders JLS/2010/DPIP/PR/1023, part 1.2.2  
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¾ To present a number of options and suggestions for quality standards and 
benchmarks and which can form the basis for discussions between experts and 
policy makers in this area. 
 
¾ To prepare for the Commission a final report consisting of options on EU 
minimum quality standards and benchmarks in the field of drug demand 
reduction. 
 
b. Project outline 
 
The project has the overall aims to: 
 
- Document the present state of quality standards in drug demand reduction 
within the European Union and internationally 
- To proceed from the available documentation to a selection of proposed 
minimum quality standards 
- To set up a consensus building process among a range of stakeholders 
throughout the European Union, in order to test the acceptability of minimum 
quality standards and to collect information on expected implementation 
problems. 
 
For the field of treatment and harm reduction, the working program covered the 
following parts: 
 
1. A search of existing standards, guidelines and other relevant documents on 
quality in drug demand reduction within the EU Member States and at 
international level.  
 
The collected information had to be categorised, analysed and screened for 
relevance; 
 
2. On the basis of the screening process, to set up a comprehensive inventory of 
quality standards and guidelines in the field of drug demand reduction   
 
3. Developing a model-framework for the draft quality standards, using selection 
criteria to select from the inventory those standards with the best potential for 
EU wide acceptability. Where available, the evidence base for each standard 
has to be provided through a systematic review of the scientific literature. 
 
4. The final inventory consisting of a draft list of quality standards for drug 
treatment and harm reduction, to be translated into an on-line stakeholder 
survey to canvas expert opinion on the acceptability and feasibility of 
implementing each individual standard within their country. 
 
23 
 
5. To discuss the outcome of the survey, combined with the evidence gathered 
through the inventory, in a European Conference, where expected obstacles 
and options for implementation should also be discussed. 
 
In the field of drug prevention, the development of minimum quality standards had to 
take a different approach. In 2007, the European Commission (EC) provided co-
funding under the Programme of Community Action in the field of Public Health 
(2003-2008) for a separate project entitled ‘European standards in evidence for drug 
prevention’. This project was carried out by the Prevention Standards Partnership, led 
by the UK Liverpool John Moores University, and completed in November 201012. 
 
This project systematically reviewed existing drug prevention quality standards in the 
EU and at international level and developed a set of quality standards in the field of 
drug prevention. The experience and information produced through this project was 
adapted for the development of the EQUS project, and where necessary, differences in 
methodological approach were reconciled and are highlighted in this report.  
 
                                                 
5 Now known as ‘European drug prevention quality standards’. Further information is available on the 
project website ( http://www.cph.org.uk/drugprevention/ ). 
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3. Conceptual clarifications 
a. About Treatment, Harm Reduction and Prevention 
 
Treatment, harm reduction and prevention are not strictly separate fields of 
interventions; they overlap in terms of aims, activities and target populations. 
 
 
Target of responses: 
 
Prevention:   general population 
Treatment:  drug users seeking treatment 
Harm reduction: drug users in treatment, drug users not in treatment and general 
population 
 
For this project, the following definitions apply (provided by EMCDDA): 
 
Treatment 
Drug treatment is defined as an activity that directly targets people who have problems 
with their drug use and that aims at achieving defined goals with regard to the 
alleviation and/or elimination of these problems, provided by experienced and 
accredited professionals, in the framework of recognized medical, psychological or 
social assistance practice. (DRAFT definition - EMCDDA Treatment Demand 
Indicator Protocol version 3.0, 2011). 
 
Harm reduction 
Harm reduction encompasses interventions, programmes and policies that seek to 
reduce the health, social and economic harms of drug use to individuals, communities 
and societies. Harm reduction is considered as a ‘combination intervention’, made up 
of a package of interventions tailored to local setting and need, which give primary 
emphasis to reducing the harms of drug use. (EMCDDA monograph, 2010) 
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Prevention 
A prevention intervention promotes activities to prevent substance use behaviour 
among other problems. The goal is to reduce risk factors and enhance protective 
factors. Prevention is achieved through the application of multiple strategies; can be 
realised in different settings and with different methods and contents. The duration can 
vary between one-off activities and long-term projects.  
Prevention interventions are commonly classified in three categories: universal, 
selective and indicated interventions. In addition there are environmental approaches 
which are prevention measures that operate on the level of the social, formal and 
cultural norms tackling both licit and illicit drugs. Universal prevention targets the 
whole population, while selective prevention targets (vulnerable) groups, both with the 
aim of deterring or delaying the onset of substance use. Indicated prevention acts at 
the individual level to: prevent the development of a dependence; to stop progression, 
diminish the frequency; and consequently to prevent ’dangerous‘ substance use 
(EMCDDA BPP).  
 
b. About Best Practice, Quality Standards and Guidelines 
 
Discussions on quality standards can sometimes be confusing without a clear 
definition of terminology. For the purpose of this debate, the EMCDDA definitions for 
the terms 'best-practice', 'quality standards' and 'guidelines' are used: 
 
Table 1  Definition of best practice, quality standards and guidelines 
 
Best Practice The best application of available evidence to current activities 
in the drugs field.  
1. Underlying evidence should be relevant to the problems and 
issues affecting those involved (professionals, 
policymakers, drug users, their families);  
2. Methods should be transparent, reliable and transferable and 
all appropriate evidence should be considered in the 
classification process;  
3. Experience in implementation, adaptation and training 
should be systematically collected and made available;  
4. Contextual factors should be studied by modeling different 
prevalence levels so as to assess the impact of an 
intervention on the population; and  
5. Evidence of effectiveness and feasibility of implementation 
should both be considered for the broader decision-making 
process.  
Quality 
Standards 
Generally accepted principles or sets of rules for the best/most 
appropriate way to implement an intervention. Quality 
standards frequently refer to structural (formal) aspects of 
quality assurance, such as environment and staff composition.  
However they may also refer to process aspects, such as 
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adequacy of content, process of the intervention or evaluation 
processes. 
Guidelines Clinical practice guidelines are statements that include 
recommendations intended to optimize patient care that are 
informed by a systematic review of evidence and an assessment 
of the benefits and harms of alternative care options  (Institute 
of Medicine. Clinical practice guidelines we can trust. 
Washington, DC: The National Academies Press; 2011.). 
 
In practice however, standards and guidelines may sometimes not be clearly 
differentiated from each other. Guidelines may include underlying standards or vice 
versa. 
 
c. A quality concept for drug demand reduction 
 
In medical sciences, quality standards are determined by different stakeholders: health 
authorities, insurance companies, service providers, professionals and patients. The 
goals, interests, priorities and scientific evidence behind these standards are quite 
diverse. In analysing the available documents on standards, this diversity has to be 
respected and eventual conflicting standards need to be thoroughly discussed. For sake 
of transparency and acceptability, it is essential to make visible where any proposals 
for minimum quality standards come from and which interests are behind them.  
 
Several levels of demand reduction provision must also be considered. The "quality of 
interventions" has a different meaning than the "quality of services and settings".  
 
Quality factors usually are broken down the following headings: 
 
1. Structural quality, e.g. standards relating to the physical environment, staff, 
training, etc.  
2. Process quality, e.g. standards relating to the process of an intervention, e.g. such 
as diagnostic assessment 
3. Outcome quality and economic quality, e.g. standards to measure the cost-benefit 
ratio 
4. Benchmarks in this study are addressed as the (desired) reference values or ratio by 
which quality can be measured. 
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Table 2  Types of quality standards 
 
 Level 1: 
interventions 
Level 2: services Level 3: systems & 
policies 
Structural 
quality 
Type of setting 
needed for 
implementation   
Resource 
standards 
(infrastructure, 
human resources)  
Legal & ethical 
adequacy standards 
(adequate to legal & 
ethical national norms) 
Process 
quality 
Procedural   
standards 
Procedural 
standards 
Standards for 
networking & 
cooperation among 
services 
Outcome 
quality 
Efficacy standards 
(having the 
intended effect) 
Effectiveness 
standards 
(reaching useful 
results) 
Coverage standards 
(proportion of those in 
need who are covered) 
Economic 
outcome 
quality 
Cost-benefit ratio 
(economic benefits 
in relation to costs) 
Cost-utilisation 
ratio (utilisation 
in relation to 
costs) 
Cost-effectiveness ratio 
(positive results in 
relation to costs) 
 
Some of these standards have to be met entirely to improve effectiveness of 
interventions (such as complying with legal and ethical conditions), others will need 
an acceptable degree of compliance or approximation to a norm (as expressed by 
benchmarks).  
 
For some key aspects of demand reduction (prevention, rehabilitation but also harm 
reduction) quality standards cannot be based on medical research and its methods 
alone, as interventions in these areas can often not be evaluated in a controlled 
research setting and by using randomised controlled trials. They are more frequently 
developed in practice and based on expert opinion.  
 
Previous work on a quality framework for addiction treatment programmes has 
demonstrated that a difference has to be made between “best practice” and 
“performance”. While various stakeholders have their views on good practice, the 
performance of an intervention is based on outcome evidence. Evidence from clinical 
trials may present different findings than “real life” experience. Both aspects will be 
considered when setting up minimum standards in this project. 
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4. Methodology 
a. National and international project partners 
 
In the Area of prevention, we choose to cooperate with the coordinator of another 
European project on quality standards, co-funded by the Executive Agency for Health 
and Consumers (EAHC) which has already been performed at the Centre for Public 
Health, John Moores University Liverpool, UK. Additional special ad hoc advisors 
were engaged with extended expertise in the drug prevention field at European level. 
The Area of treatment and rehabilitation, the coordinating Research Institute for 
Public Health and Addiction at Zurich University recruited experts with known 
competency in the field and in past collaborative studies. The main criteria were the 
expected knowledge of and access to relevant documents, to guarantee completeness 
of the inventories on existing quality standards, and their scientific qualifications, to 
guarantee competent performance of the tasks. Experts with whom good scientific 
collaboration had been experienced in the past, were preferred. For an inclusion of 
non-European expertise, prominent researchers from USA, Canada and Australia were 
approached and engaged. 
 
In the Area of harm reduction, we also could build upon an established team of 
specialists at the Universities of York and Kent, UK, already involved in the 
identification of quality standards. Additional consultants with outstanding experience 
at European and international level were engaged. 
 
The complete list of experts participating as project partners can be found in Annex 1. 
 
A steering group was set up by Directorate General Justice (DGJ), including 
representatives from the Commission, from EMCDDA Lisbon and the project 
coordinating institute.13 A kick-off meeting of the steering group took place at 
EMCDDA in Lisbon, on May 4th. An important number of issues could be clarified 
and decisions taken for the implementation of the project. Furthermore, EQUS was 
presented at the REITOX meeting in Lisbon (May 26th); national focal points to be 
included in the consensus building process. 
 
The EQUS expert group which was proposed in the tender could be fully realised and 
additional members could be recruited. No invited expert has declined to participate.   
 
All Member States of the European Union can be adequately covered by this group, as 
well as Norway and Switzerland. The international arena is respected by including 
high level experts from USA, Canada and Australia. 
 
The following institutions provided access to their relevant documents: EMCDDA, 
Lisbon, COCHRANE Drugs and Alcohol Editorial Group, Rome, WHO Division of 
                                                 
13 See list of steering group members in Annex 2 
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Mental Health and Substance Abuse, Geneva, WHO Regional Office for Europe, 
Copenhagen. 
 
All experts acting as collaborating partners have taken the responsibility to search and 
screen the existing relevant national documents on quality standards and benchmarks 
in their respective areas of drug demand reduction. They also acted as reviewers of the 
draft national inventories and the sets of European minimal quality standards and 
benchmarks. Furthermore, they participated in the consensus building process during 
two expert meeting and in the European stakeholder conference, and by identifying 
national stakeholders to be included in the surveys and the conference.  
 
b. Methodology used for drug treatment and harm reduction 
 
Document search 
 
A range of previous studies and reviews were researched and selected from national 
and international sources. These documents were screened for quality standards and 
benchmarks. The complete range of interventions, services, drugs and target 
populations had to be covered.  
 
This task was approached with the following steps (see first interim report Appendix 
3): 
 
- Drafting detailed instructions for the national document search and screening 
by collaborating project partners 
- Drafting electronic templates for the extraction and transmission of relevant 
information from the selected documents 
- Drafting a manual for the use of the templates  
- Discussion of draft instructions and templates during the kick-off meeting 
(May 12-13th  in Zurich) 
- Piloting the draft templates and manuals at national level for 2-3 selected 
documents (deadline July 5th) 
- Evaluating the pilot phase, including feedback and comments made to the 
templates and the manual 
- Finalising and dissemination of templates and manual for treatment and 
rehabilitation standards to collaborating partners (July 9th)  
- Adapting and disseminating template and manual for harm reduction standards. 
 
Collaborating partners have been invited to a kick-off meeting which took place in 
Zurich on June 12-13 2010. They received previously a draft agenda for the meeting, 
draft instructions for the document search and a draft template for electronic 
evaluation of the selected documents. The meeting was attended by 12 participants 
and proved to be instructive and helpful. Further steps have been discussed and agreed 
upon. An important new decision concerned the search and evaluation of documents 
on harm reduction standards by all collaborating partners at the national level, in 
addition to the international documents collected and evaluated by the coordinators in 
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the harm reduction area (Dr. Charlie Lloyd and Neil Hunt, UK). The kick-off meeting 
and the ensuing pilot phase testing the template instruments and the manuals for their 
use were helpful for clarifying the tasks and procedures, in order to best prepare the 
document search and information collection. 
 
The instructions and manuals are attached as Annex 4. 
 
The selection criteria for documents to be integrated into the inventory were:  
 
- Published documents providing information on quality indicators and/or 
standards on specific interventions and/or specific settings and/or regional / 
national networks 
- International documents only if made relevant at national level 
- Priority was given to official documents (e.g. by health authorities, 
professional associations, major service providers, insurances), research 
reviews and research reports.  
- Standards/guidelines were included which are relevant exclusively for the 
drugs field and not the broader healthcare or social care fields. 
 
Categories of services and interventions 
 
For systematic collection of information about quality standards, it was necessary to 
establish a typology of services and interventions. 
 
• Types of services for treatment/rehabilitation:: 
• Out-patient services for ambulatory treatment  
• In-patient services for residential treatment  
• Prison-based services for intramural treatment  
• Office-based services for treatment in private practice (e.g. family doctors)  
• Teams specialised in addiction treatment (having specialised training) 
• Teams not specialised in addiction treatment  (e.g. general hospital emergency 
teams) 
 
For harm reduction, the same typology was used, with two more (pharmacies and 
clubs). 
 
• Types of interventions in treatment/rehabilitation: 
• Counselling and early interventions  
• Psychosocial interventions (psychological and social support, psychotherapy)  
• Substitution maintenance (replacing street opioids by prescribed medication)  
• Heroin-assisted treatment (replacing street heroin by pharmaceutical 
diamorphine)  
• Other pharmacological intervention 
• Detoxification (assisted withdrawal of substances of abuse)   
• Aftercare  
• Vocational rehabilitation (facilitating re-entry into the labour market) 
• Other rehabilitation (e.g. social contacts, legal assistance etc.) 
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• Sheltered day/night programmes 
• Self-help approach  
 
Types of interventions in harm reduction: 
 
• Needle exchange program (changing used syringes and needles against sterile 
ones) 
• Supervised injection room (injecting under sterile conditions, support 
available) 
• Outreach work / street work 
• Drug checking (analysing drugs on the spot in discos, clubs, during raves etc.) 
• Blood borne virus infection testing 
• Vaccination (mainly hepatitis B) 
• Referral to other services if needed 
• Safer sex education 
• Safer use education 
• Sheltered housing 
 
Categories of target populations 
 
• All types 
• Females  
• Males 
• Adolescents 
• Dual diagnosis patients 
• Somatic co morbidity 
• Prison inmates 
• Other marginalised population 
 
Categories of substances 
 
• Cannabis 
• Heroin 
• Cocaine 
• Amphetamine 
• Methamphetamine 
• Ecstasy  
• Hallucinogenic substances 
 
Categories of quality standards 
 
To allow for a meaningful differentiation of standards for various settings and 
interventions, the model design for standards in the fields of treatment /rehabilitation 
and for harm reduction was divided into: 
 
- structural standards formulated in relation to different types of services, e.g 
accessibility of the service, the physical environment and staff composition 
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- process standards formulated in relation to different types of services and  
interventions, e.g. assessment procedures, data handling, staff training, 
cooperation between agencies 
- outcome standards formulated at the system level, e.g. goals of treatment and 
harm reduction, evaluation of outcomes, monitoring, referrals. 
 
Finally, for each standard it had to be documented if it is mentioned as mandatory or 
recommended only, and which grade of evidence – if any – is available for that 
standard. The definitions used in the EQUS project are a simplified version based on 
the work of the GRADE working group14, in regard to the difficulties to train the 
experts in such a specialised methodology and due to the less defined nature of the 
documents which were assessed. 
 
Table 3  Grading of evidence  
 
Grade Definition 
A Highest degree of evidence: review from multiple randomised controlled 
studies (RCT) with convergent results 
B High degree of evidence; results from single RCT and controlled clinical 
studies 
C Moderate degree of evidence: prospective comparative longitudinal 
studies (observational studies without control design) 
D Low degree of evidence: single intervention/service follow-up studies, 
case studies 
E Very low degree of evidence: non-systematic observations 
Z Not known. 
 
Analysing and transmitting information from the selected documents 
The non-English documents selected by project partners for inclusion could not be 
translated into English (for financial reasons). Information from these documents had 
to be extracted under the supervision of senior scientists and entered into the 
structured English templates in order to receive comparable information from all 
documents. Detailed instructions for the analysis of original documents had been 
prepared and accepted. All templates were transmitted electronically to the Zurich 
coordinating institute, where they were screened for errors, plausibility and missing 
information. 
 
Integration of information in a centrally administered masterfile 
In order to prepare the organisation of incoming information from the templates, the 
coordinating institute in Zurich has set up a specific mail address for sending the 
templates (EQUS@isgf.uzh.ch). Also, steps had been taken to set up a data bank 
and master file for all incoming information from templates. The master file was the 
basis for setting up national inventories of existing quality standards and benchmarks, 
                                                 
14 See GRADE working group (2004). Grading quality of evidence and strength of recommendations. 
BMJ 328:1490 
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separately for the areas of prevention, treatment/rehabilitation and harm reduction, as 
well as European inventories in these three areas. 
 
For the areas of treatment/rehabilitation and harm reduction, a special category of 
“reference documents” was created, as not all documents were equally important, with 
the following criteria: 
- national document 
- evidence grade A or B for treatment/rehabilitation, evidence grade A or B or C for 
harm reduction (cf. point 5.2.2). 
- based on systematic literature research or expert consensus. 
 
In total 29 documents for treatment/rehabilitation and 9 documents for harm reduction 
were identified as reference documents on the basis of these criteria. 
 
Setting up the inventory 
 
The retrieved documents were analysed. In order to extract comparable information 
from the selected documents, structured electronic templates were prepared in an 
Excel format and submitted to project partners for approval. The manuals how to use 
the templates are in Annex 4. 
 
Following a meta-analysis of the collected data, a total of 349 relevant documents (259 
for treatment and rehabilitation, 90 for harm reduction) at national and international 
level could be identified, screened and the structured contents integrated into an 
electronic master file. The file results in a list of transmitted templates per country 
(See Annex 5). 
 
Are the sources of information in the relevant documents equally distributed among 
the European Union ? The following  tables show the distribution across three regions 
(South-West includes Austria, Belgium, Cyprus, France, Germany, Greece, Italy, 
Netherlands, Portugal, Spain, Switzerland; Central-East includes Bulgaria, Czech 
Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia; 
North includes Denmark, Finland, Ireland, Sweden, United Kingdom).   There are no 
major differences, except the overall considerably lower number of documents for 
harm reduction compared to treatment/rehabilitation. 
 
Table 4  Sources of relevant documents: regional distribution (Treatment/rehabilitation) 
 
Source South-West Central-East North 
Lit. review 41 23 20 
Exp. opinion 40 43 23 
Exp. consensus 61 51 25 
Research project 22 15 12 
Practice experience 40 36 19 
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Table 5  Sources of relevant documents: regional distribution (Harm reduction) 
 
Source  South-West Central-East North 
Lit. review 7 8 7 
Exp. opinion 9 7 6 
Exp. consensus 8 13 6 
Research project 3 7 7 
Practice experience 10 4 7 
 
 
The resulting inventory contains a comprehensive list of quality standards and 
benchmarks emerging from the analysis of the templates (Annex 6).    
 
c. Methodology used for prevention standards15 
 
The prevention strand of this project differed from the areas of treatment and harm 
reduction in that a set of EU quality standards in drug prevention had already been 
developed as part of a separate study on standards and guidelines for drug 
prevention16. This project had been carried out by the Prevention Standards 
Partnership and completed in November 2010. These European drug prevention 
quality standards are published as an EMCDDA Manual for practitioners (EMCDDA, 
2011). 
 
Therefore, unlike other strands in this project, original standards documents were not 
reviewed in the prevention part of EQUS. Instead, the existing European standards 
were adapted to the requirements of the EQUS project. Adaptation was carried out by 
Dr Harry Sumnall and Angelina Brotherhood (Liverpool John Moores University, 
UK), the lead partners in the Prevention Standards Partnership. 
 
The first part of this section provides an overview of how the European drug 
prevention quality standards were developed in the separate project (highlighting 
differences to the areas of treatment/rehabilitation and harm reduction); followed by a 
description of the adaptation process for the EQUS project. Further information on the 
Prevention Standards Partnership and the development of the European standards is 
available in the EMCDDA Manual (EMCDDA, 2011) and in the methodological 
report (Brotherhood et al., 2011). 
 
Development of European drug prevention quality standards in previous project 
                                                 
15 The sections describing the prevention standards in this report were prepared by Dr Harry Sumnall 
and Angelina Brotherhood of the Centre for Public Health, LJMU, UK. 
16 Project name ‘European standards in evidence for drug prevention’, co-funded by the European 
Commission (EC) under the Programme of Community Action in the field of Public Health (2003-
2008). 
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The document search for prevention standards was comparable to that carried out in 
the areas of treatment and harm reduction (e.g. using similar selection criteria). 
However, the drug prevention study did not distinguish between different types of 
services and interventions as the majority of identified quality standards referred to 
general drug prevention (i.e. not limited to a particular intervention type). In total, 77 
documents were retrieved and screened, out of which 19 documents containing quality 
standards were selected for inclusion. Where necessary, materials were translated into 
English. 
 
The analysis of existing standards also differed in the prevention strand. Firstly, the 
identified standards were based upon expert/stakeholder opinion, expert consensus, 
reviews of previously existing standards, and/or literature reviews. It was therefore not 
appropriate to grade the evidence of identified standards. Instead, each selected 
document was described separately (including details of standards development; see 
Brotherhood et al., 2011). Secondly, the prevention study did not utilise a 
predetermined template for extracting standards. Instead, a data-driven approach was 
taken and quality standards were synthesised through a structured qualitative content 
analysis; i.e. relevant standards in the documents were identified and extracted into a 
spreadsheet, categorised thematically and sorted, and similar standards were merged. 
This method produced a long list of standards combining all reviewed documents. The 
resulting standards were structured along a project cycle with distinct project stages 
(i.e. differing from the typology of structural, process, outcome standards used in 
treatment/rehabilitation and harm reduction). 
 
The draft standards were refined in consultation with drug prevention professionals 
through a two-round online Delphi survey17 and focus groups18 in the partner 
countries (Hungary, Italy, Poland, Romania, Spain, and UK). The revised standards 
were finally ‘field tested’ in their entirety in additional focus groups to obtain a better 
understanding of opportunities and challenges for their uptake in practice. Further 
details on these consultations are provided in this report in the section “Stakeholder 
surveys”. 
 
In the final version, the European drug prevention quality standards cover the 
following eight project stages: 
 
1. Needs assessment;  
2. Resource assessment;  
3. Programme formulation;  
                                                 
17 Delphi surveys are conducted in several rounds, whereby the results of previous rounds are fed back 
to participants. The aim of Delphi surveys, as with other consensus methods, is to measure the extent to 
which experts agree about a given issue. This agreement is comprised of two elements: firstly, the 
respondents’ agreement with the issues in question, and secondly, the level of agreement between 
respondents (Jones & Hunter 1995).  
18 Focus groups are a form of group interview where data is generated by encouraging group interaction 
(Kitzinger 1995). 
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4. Intervention design;  
5. Management and mobilisation of resources;  
6. Delivery and monitoring;  
7. Final evaluations; and  
8. Dissemination and improvement 
 
The actual standards are presented on two further levels of detail: 
• Components – actions to take within the project stages (31 components across 
the eight project stages, and four additional components (‘cross-cutting 
considerations’) that are of relevance to each project stage, namely: (A) 
sustainability and funding; (B) communication and stakeholder involvement; 
(C) staff development; and (D) ethical drug prevention); 
• Attributes – most detailed level of standards which can be used to evidence 
achievement in practice; distinguishing between ‘basic’ and ‘expert’ level 
standards. 
 
Adaptation of the European drug prevention quality standards to the EQUS project 
 
In June 2010, the EQUS project coordinator attended a meeting of the Prevention 
Standards Partnership to present the design and procedures of EQUS, and to discuss 
further steps to be made for an adaptation of the prevention standards to the 
requirements of EQUS. 
 
The following adaptation requirements were identified following this meeting: 
 
1. Clarify evidence base underpinning prevention standards 
2. Apply template used in treatment/rehabilitation and harm reduction to 
prevention standards (including typology of structural, process and outcome 
standards) 
3. Reduce list of standards to ‘minimum’ standards 
4. Adopt language of prevention standards to that used for 
treatment/rehabilitation and harm reduction 
 
The following paragraphs describe how each of these requirements was addressed by 
the Prevention Standards Partnership in the adaptation process: 
 
1. In order to clarify the evidence base underpinning the standards, general 
information about the 19 underlying original standards documents was extracted using 
similar templates as in the areas of treatment/rehabilitation and harm reduction. The 
existing ‘Manual for the use of the electronic template on treatment/rehabilitation’ 
was used to guide completion of the General Information sheets for each standard 
document. Additional answer responses were used in some of the categories to 
optimise the manual for prevention practice. 
 
2. A structured electronic template was developed to categorise the standards in 
line with the methodologies used in treatment/rehabilitation and harm reduction (i.e. 
Structural, Process, and Outcome standards as well as relevant sub-categories). Each 
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‘basic’ standard was labelled according to the template categories, allowing adaptation 
of the prevention standards to the format of the other two areas treatment/rehabilitation 
and harm reduction. Further feedback received at the European conference of 
stakeholders (see below) was used to refine the categorisation for the final version of 
the EQUS prevention standards. 
 
Consequently, as in the areas of treatment/rehabilitation and harm reduction, lists were 
developed for 
 
- Structural standards for services 
- Process standards for services and interventions 
- Outcome standards for treatment/harm reduction systems and networks. 
 
Thus, whilst the content of the European drug prevention quality standards was not 
changed for this project, the structure was. Annex 7 contains an overview of how the 
EQUS prevention standards correspond to the European drug prevention quality 
standards published in the EMCDDA Manual. 
 
3. The procedure of allocating standards to template categories was conducted 
only with ‘basic’ standards as the EQUS project sought to identify only minimum 
standards (i.e. all ‘expert’ level standards were removed for the purposes of the EQUS 
project). However, additional reduction was required as this list was not sufficiently 
concise to fulfil EQUS project aims. Therefore, a further revision was made and the 
final list of EQUS prevention standards was based upon the ‘component’ level rather 
than the very detailed ‘attribute’ level used in the European drug prevention quality 
standards (as described above). The proposed list of minimal quality standards for 
prevention reflects a summary of the basic standards included in the EMCDDA 
publication. The full prevention standards (including all basic and expert level 
standards) are available through the EMCDDA manual publication (EMCDDA, 2011). 
 
4. Finally, the wording of the prevention standards was changed in order to 
ensure correspondence with the treatment/rehabilitation and harm reduction standards, 
although careful attention was given to preserve the meaning of the standards. 
Additionally, feedback received at the European conference of stakeholders (see 
below) highlighted the need to change some standards terminology so that the EQUS 
prevention standards could be read as a stand-alone document independently of the 
EMCDDA manual publication. 
 
Thus, by reanalysing and reorganising the prevention standards as described above, it 
was possible to ensure that all three areas are comparable in terms of their 
development, content, and presentation. The list of proposed prevention quality 
standards presented in chapter 6b is the final list produced through this process. 
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5. Consensus building process in the EU 
 
a. Expert seminars 
 
A first expert seminar was held in Brussels in December 6-7, 2010. It was attended by 
19 experts (minutes in Annex 8). 
 
In the first part, the results of the document search and data analysis were presented 
and discussed. 
 
Most of the documents were found in national databases, only a few in international 
databases. The main sources were institutional pages of national agencies, regional 
official documents and professional literature. Some countries such as Germany or 
Spain have faced difficulties because of the regional system in the country. The 
greatest amount of documents came from regional authorities, and only a small part 
from national government therefore, it was difficult to come up with single national 
guidelines. 
 
The main problem most of the countries faced was grading the evidence. It was 
difficult to grade the evidence because there was a lack of objective criteria, and some 
evidence already had a national grade, therefore it was difficult to convert such grade 
to the one provided in the template. 
 
To improve the quality of the template ISGF introduced a web-based template which 
replaced the current excel-sheet based template. Web-based template is more user-
friendly. 
 
Some concern was raised with regard to documents from countries where drug 
treatment or harm reduction could possibly be included under the general health care 
system. Some guidelines are provided for broader fields – psychological treatment, for 
instance. Those are not represented in our database; the templates are limited 
exclusively to drug relates issues as well as the overall focus of the project. 
 
The first analysis results showed: the origin of documents is mainly the public sector, 
also professional associations. The most frequently mentioned intervention typey are 
psychosocial interventions and substitution treatment. There are more documents for 
specialized settings than for non-specialized settings. Some problems occurred with 
regard to the targeted population. Most of the countries have marked all categories if a 
given document did not indicate the targeted group precisely. 
 
Evidence grades of structural standards, process standards and outcome standards 
were found to be considerably low. Level A is almost nonexistent. 
 
Several important procedural decisions were taken. One decision was about extracting 
minimum quality standards from the inventories. There was consensus not to prose 
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lists of minimum standards by the expert group, but to prepare comprehensive lists 
from the inventories and to present those in stakeholder surveys, together with 
pertinent information about each standard, so that stakeholder consensus can be used 
as a basis for identifying minimum standards. The criterion should be a high degree of 
consensus (>80%). 
 
A next step was an agreement on the structure of the questionnaire for the online 
survey. The questionnaire informed about the basis of the individual quality standards 
and includes questions on the acceptability of the standard for specific interventions 
and on eventual problems for implementation.  
 
The expert group also decided to have a piloting of the questionnaire among the 
project partners, to take place January 7-14, 2011.  
 
In a second expert seminar (March 3-4, 2011, in Brussels), the experts discussed the 
outcome of the piloting exercise (minutes in Annex 9). It resulted in a number of 
comments (ca. 80 feedbacks) and improvements. Some changes were made in the 
formulation and explanation of the individual standards, in some answer categories in 
the overall format.  Participants finalised the lists of stakeholders for the surveys and 
made preparations for the European conference.  
 
b. Stakeholder surveys 
 
In the areas of treatment/rehabilitation and harm reduction, the consultation and 
consensus building mechanism was started according to plan. The concept and the 
necessary preparations were discussed in the second expert seminar (see second 
interim report Annex 10) 
 
Two online surveys were carried out by the Zurich coordinating institute between 
January and April 2011. The questionnaire was developed on the basis of feedback 
from the EQUS expert group and the EMCDDA's REITOX national focal points.  
 
The aim of the survey was to test expert opinion across the EU to assess the level of 
agreement for the inclusion of particular standards in the final lists of minimum 
standards for drug treatment/rehabilitation and harm reduction. The questionnaire also 
asked about the acceptability of each standard, separately for services and 
interventions, and about expected problems for implementation. 
 
A first step was an agreement on the structure of the questionnaire for the on-line 
survey. This questionnaire is organised around process standards for interventions, 
structural standards for services and outcome standards at the system / network level. 
The questionnaire informs about the basis of the individual quality standards and 
includes questions on the acceptability of the standard for specific interventions 
(process standards) or services (structural standards) and on eventual problems for 
implementation.  
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In a second step, a piloting of the questionnaire among the project partners (January 7-
14, 2011) resulted in a number of comments (ca. 80 feedbacks) and improvements, for 
a better understanding and acceptability of the tasks to be performed when 
participating in the survey. The main changes concerned the formulation and 
explanation of the individual standards, some answer categories and a more user-
friendly format. The final questionnaire for the on-line survey is attached (See Annex 
14). 
 
A third step was the setting up of national lists for stakeholders to be consulted in the 
on-line survey, with separate lists for treatment / rehabilitation and for harm reduction 
(this process was already performed in the separate prevention project). The areas to 
be included in the nomination of stakeholders were defined: medical professions, 
social professions, public authorities (health, social, justice, police), relevant NGO’s 
and professional associations, insurance bodies, research groups, user groups, church 
and media representatives. All project partners were required to present lists and 
EMCDDA asked the national Focal Points to nominate participants. WHO and special 
advisers are also invited to make nominations and more are expected.   
 
The fourth step was the start of the on-line survey first round as agreed on January 20, 
2011. Participants were invited to answer within 3 weeks time. The evaluation of 
answers by the contractor team was communicated to the Commission, the steering 
group and the project partners for comment and for discussion at the second expert 
meeting in March 2011. 
 
The next step was to canvas expert opinion on the acceptability of quality standards 
derived from the inventory. In order to enable stakeholders to make informed 
decisions about the acceptability of each standard, they were provided with the 
following information: 
 
- on the range of countries having mentioned the standard in guidelines or 
similar documents and in reference documents 
- on the status of the standard in these countries (recommended or mandatory) 
- on the source of information (literature search, expert consensus, research 
project) 
- on the available evidence grade. 
 
In the first survey round, 469 identified stakeholders from EU Member States and 
Switzerland were invited to participate. The total number of completed questionnaire 
was 164 (from 118 stakeholders). The low response rate (30%) was due to short time 
span. The types of stakeholders however were quite representative, the big majority 
were NGOs, government organisations and health sector. 
 
In total 514 stakeholders were invited in the two survey rounds, from all EU Member 
States, including health and social professionals, representatives of public authorities, 
health insurance, and user groups organisations.  In the second survey round, 
professionals received feedback on the results from the first round. Across all 
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countries and regions, a total of 241 out of 514 (≤46.9%) invited professionals 
completed the survey rounds. 
 
On the basis of the results from the two surveys, a difference was made between 
standards which reached high, moderate or low degree of consensus:  
 
- Quality standards with a high degree of consensus (>80%) 
- Quality standards with a moderate degree of consensus (>50-80%) 
- Quality standards with a low degree of consensus (<50%) 
 
If a given standard is considered to be overall acceptable (high level of consensus), but 
with the exception of specific settings or interventions, this is mentioned in the lists in 
chapter 6.   
 
In prevention, stakeholder surveys were carried out as part of the earlier EC co-
funded project to develop European drug prevention quality standards. As with the 
areas of treatment/rehabilitation and harm reduction, national lists for stakeholders to 
be consulted were set up for each country of the Prevention Standards Partnership 
(Hungary, Italy, Poland, Romania, Spain and UK). The sampling frame was 
constructed to reflect the range and scope of drug prevention delivery systems in 
project partner countries. 
 
A two-round online survey was conducted in January and February 2010. Participants 
received information on the separate prevention standards project and on the methods 
used to develop the draft standards. However, additional information on every 
individual quality standard as in the areas of treatment/rehabilitation and harm 
reduction was not provided. Instead, participants were asked to make judgements 
based upon their professional experience as well as what standards they believed 
would improve the current quality of prevention. Respondents consequently rated the 
priority of the draft standards from ‘high priority’ to ‘not a priority at all’, and also 
whether they believed the standards should be mandatory as part of good quality drug 
prevention services. They were also able to provide text comments explaining their 
ratings. In the second survey round, those professionals who had completed the first 
survey received feedback on the results from the first round and were able to re-rate 
the standards in light of these findings. In total, 487 out of 987 invited professionals 
completed the first survey round, and 423 respondents completed both survey rounds 
(87% of those who completed the first round). 
 
As part of the earlier prevention standards project, two rounds of focus groups were 
also held between March and September 2010. In total, 122 participants took part in 
the first round of focus groups to discuss the standards in detail, particularly with 
regard to their relevance, usefulness, and feasibility; and 72 participants helped define 
how the standards could be implemented in practice and provided final suggestions for 
improvement.  
 
For the EQUS adaptation of the prevention standards, no additional stakeholder 
surveys were carried out, although feedback received at the European conference of 
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stakeholders was incorporated to produce the final version of the EQUS prevention 
standards (see below). The Delphi results obtained in the original research were used 
to indicate acceptability of the standards, more specifically the question on whether 
participants believed a standard should be mandatory as part of good quality drug 
prevention services. It is important to note that these Delphi ratings refer to the first 
draft of the standards and not the final version. It is likely that the final, improved 
standards would receive a greater level of support in a new Delphi survey.  
 
The proposed prevention standards can consequently be distinguished as follows: 
 
- standards with high acceptability (rated as mandatory by > 80% of responding 
participants) 
- standards with medium acceptability (rated as mandatory by 50-80% of responding 
participants) 
- standards with low acceptability (rated as mandatory by less than 50% of 
responding participants). 
 
Those with a medium acceptability were discussed during the European conference. 
There were no standards with low consensus as these had already been modified as 
part of the standard development process. 
 
c. European conference of stakeholders 
 
The development of any quality standards is a process which requires the involvement 
of a wide range of stakeholders to ensure that the standards gain support and 
acceptability. A European conference with the participation of a wide range of 
different stakeholders was therefore planned as an essential part of the consensus 
building process. This technical conference, hosted by the European Commission in 
association with the Hungarian Presidency of the EU, was designed to bring together 
such a range of stakeholders to discuss the preliminary findings of the EQUS study.19 
It attracted over 100 participants including policy-makers, practitioners, NGOs and 
researchers in the fields of drug prevention, treatment and harm reduction from across 
the EU (list of participants in Annex 11). 
 
The objectives of the conference included the discussion of the proposed list of 
minimum quality standards, as well as perspectives for their implementation. 
 
The conference took place in Brussels on June 15-17, 2011. A steering committee 
meeting had prepared the details. A working paper provided preparatory information 
to participants (Annex 12).  
 
 
                                                 
19 :the website of the conference presents the programme and the speeches, as well as the preparatory 
documents and the conference summary  http://ec.europa.eu/justice/newsroom/anti-
drugs/events/110615_en.htm 
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Conference programme 
 
The conference started with a summary presentation of the EQUS project, and the 
international context for their discussion was presented from the EU, from WHO 
headquarters and from EMCDDA20. 
 
The proposed lists of minimum quality standards were discussed in parallel groups 
(prevention, treatment, harm reduction). In these parallel sessions, standards with a 
high consensus were presented for additional comment, standards with a moderate 
consensus were submitted for discussion for eventual inclusion, while those with low 
consensus on acceptability were proposed to be excluded.  
 
In the second part of the conference, models of implementation were presented from 
the Czech Republic, the UK, The Netherlands and Switzerland21. In a new round of 
parallel sessions, barriers and options for implementation were discussed, from the 
perspectives of policy makers and practitioners respectively (see conference report in 
Annex 13). 
 
Conclusions of the conference 
 
A concluding panel discussion with representatives from policy, practice and science 
highlighted important points to take forward the development of minimum quality 
standards in drug demand reduction: 
 
- increasing acceptance by professionals through knowledge transfer/training 
new practitioners in drug treatment 
- the evidence base behind the standards needs to be supported through further 
research 
- need to operationalise the standards to develop measures for 
monitoring/evaluating 
- EU standards must provide a tangible/operational tool for national stakeholders 
- This is a long term process to be backed by sustainable funding  
- international perspective:  EU minimum quality standards relevant for 
countries outside EU need to develop common language in this field. 
  
On the basis of the project conclusions, the Commission will reflect on how to develop 
this proposal and what form it will take. The process to develop, adopt and implement 
the EU guidelines on cancer screening provides a useful example to consider, but there 
may be others.  
 
European level minimum quality standards must add value to what exists in the EU 
member states and take account of different health systems and capacities across 
Member States. Some countries have developed effective responses after 
implementing for three decades treatment measures, while others lack both funding 
                                                 
20 Presentations on conference website 
21 Presentations on conference website 
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and expertise to provide such services. A European framework is a way to encourage 
and guide good practice in accordance with national and local circumstances. It should 
provide an incentive to those countries where such standards do not yet exist and 
motivate other countries to review and update current practice to improve the 
effectiveness and outcomes of their measures. 
 
Financial support could provide an important boost for countries wishing to share 
good practice in the field of quality standards in drug demand reduction. The EU’s 
drug prevention and information programme could offer grants for such cross-border 
initiatives under its 2012 work programme. 
 
In this time of economic crisis, resources must be invested wisely where the benefits 
are greatest. Outcome and evaluation standards provide a useful management tool to 
guide investment decisions of policy-makers, but further research will be necessary to 
develop these.  
 
Working together with the European Monitoring Centre for Drugs and Drug 
Addiction, the Commission will consider what further research work may be necessary 
to strengthen the evidence base underpinning the minimum quality standards. 
 
d.  Stakeholder comments on the proposed standards 
 
During the European conference, stakeholders were invited to discuss in parallel 
sessions the following topics: 
 
- are the proposed lists of minimum quality standards (high consensus in 
surveys) acceptable ?  
- for which types of services / interventions are they accepted ? 
- which standards from the presented additional lists of quality standards 
(medium consensus in surveys) should be included in the definite lists of 
minimum standards ? 
- for which types of services / interventions ? 
 
The following paragraphs present a summary of comments made during the sessions. 
 
Treatment/rehabilitation:  Further elaboration was requested for: 
 
- considering the role of  peer support and non-professional staff and client 
involvement in programming and shared responsibility 
- accountability of staff  
- providing specific criteria for internal and external education of staff 
- evidence-based treatment only   
- periodical revision of treatment planning 
- criteria for sharing responsibility in treatment choices 
- standards on transparency in the use of funds. 
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The following standards were recommended to stay on the list of moderate consensus 
and not to be moved to the list of minimum standards: 
 
- cost effectiveness ratio as an outcome measure 
- cost-benefit ratio as an outcome measure. 
 
Both standards are considered to be difficult to measure and the results difficult to 
interpret. These techniques need further development. 
 
Final general recommendations made: 
 
- check the wording of standards 
- provide more examples 
- specify the applicability per type of services and interventions. 
 
Harm reduction: 
 
- One important suggestion that came up was that opioid substitution therapy should 
be integral part of the harm reduction standards and not only of the treatment and 
rehabilitation standards.  
 
- In the structural standards of interventions, there was consensus that the two 
accessibility standards on location and opening hours (previously classified as 
moderate consensus standard) should be taken together and classified as high 
consensus standard. The new formulation should be “Services have to match the 
needs of clients” and “Costs should never be a barrier to a service.” 
 
- There was agreement that in the standard on staff composition, the inclusion of 
peers should also be taken into account. The new formulation should include that 
staff has to be qualified and that staff qualification has to be made transparent.  
 
- There should be an additional standard on indication criteria / age limits. The 
formulation should include that services have to be age appropriate, that staff has 
to be trained to meet age appropriate clients needs, but that there should be no age 
limits. The standard on referrals should also include referrals to legal services. 
  
- It should be mentioned that interventions should not be based on written informed 
consent, but rather on a transparent information about all the offers by a service. 
 
- There was consensus that the standard on the confidentiality of client data should 
be intervention specific. Also, it was pointed that data should not be accessible 
without the agreement of the client and that the client’s needs should come first.  
 
Prevention: 
 
Participants agreed that the selection of ‘minimum’ standards depended on their 
intended use and audience. If used to inform funding decisions, it was felt that fewer 
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standards should be included in the list to allow greater flexibility in practice, whereas 
more standards could be included if the document was a guidance document for 
practitioners. With this in mind, it was argued that, although desirable, the standards 
on outcome evaluation should not be included in a ‘minimum’ list of standards 
because they were not always feasible due to practical or financial circumstances. 
From the list of standards with moderate consensus, six out of ten standards were 
acceptable with slight modifications (e.g. exceptions clarified). 
 
More generally, it was noted that the structure used in the EQUS standards (“structural 
standards”, “process standards”, “outcome standards”) was not commonly used in 
prevention, particularly in universal approaches (e.g. school curriculum). It was also 
argued that some standards should be merged to reduce redundancy, while other 
standards should be split up to increase specificity of the statements. The discussion 
showed that some terms used in the standards (e.g. “needs”, “harm”, “evidence-
based”) were open to interpretation (e.g. had no standard clinical definition) and 
required clarification. It was also questioned whether the numbering was meant to 
indicate hierarchy or priority of standards. 
 
It was agreed that the publication of the EMCDDA Manual on “European drug 
prevention quality standards” would increase acceptance of the EQUS prevention 
standards, particularly if the correspondence between the two sets of standards was 
evident. 
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6. Proposed Lists of Minimum Quality Standards 
 
The following lists are the outcome of the various steps of the consensus building 
process. The two stakeholder surveys allowed to identify the degree of acceptability 
(high-moderate-low degree of consensus), and the European stakeholder conference 
finalised the list of high consensus by adding some standards from the list with 
moderate consensus and by stating some standard explanations and examples more 
precisely.  
 
The lists below are the updated lists of minimum quality standards which reached a 
high consensus. They provide information on the consensus basis of the standards 
(stakeholder survey and stakeholder discussions at the European conference, 
respectively). They also add information on exceptions from high consensus, if 
standards where not accepted for all types of services or interventions. Such 
exceptions are marked below each one of these standards.  
 
The lists of minimum standards are structured in groups according to the types of 
standards (as set out in chapter 3c). The sequence of these groups and within groups is 
not meant to indicate any kind of priority. 
 
a. Prevention standards 
 
Prevention: Structural Standards of Services 
 
P1 Ethical principles: adherence to ethical principles (e.g. service must protect 
participants’ rights, provide services/interventions that have clear benefits for 
participants, must not provide a service/intervention where evidence shows that 
it could harm participants (e.g. increase drug use, stigmatise participants)) 
 
P2 Policy and legislation: reference to drug-related policy and legislation as 
required for the implementation of the service/intervention 
 
P3 Routine cooperation with other agencies: the organisation cooperates with 
other agencies and institutions in correspondence with the multi-service nature 
of drug prevention (e.g. health and social services, criminal justice services, 
educational services) 
 
P4 Financial requirements: a clear and realistic cost estimate is provided; available 
funding streams are sufficient to cover costs 
 
P5 Internal resources and capacities: sufficiently available for implementation 
(e.g. human, technological, financial resources) 
 
P6 Staff composition: transdisciplinarity and qualifications of staff are appropriate 
for the service (e.g. type of roles, number of staff, level of education) 
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P7 Staff support: staff members are supported in their work as appropriate 
 
Prevention: Process Standards of Services/Interventions 
 
P8 Ethical standards: adherence to ethical standards (e.g. intervention is only 
carried out if there is a need for it, procedures in place to ensure informed 
consent, confidentiality, protect safety of participants and staff members, 
information about drugs and related behaviours is accurate where it is 
provided) 
Exception: informed consent may not be feasible in some universal and 
environmental approaches (e.g. mass media) 
 
P9 Assessment procedures: detailed and diverse information on drug use in the 
community/target population/environment of interest has to be collected 
through primary or secondary study (e.g. types of drugs used, drug use rates 
and trends) 
 
P10 Assessment procedures: target population’s culture (1. relation to drug use, 2. 
relation to the service/intervention activities) has to be assessed 
 
P11 Assessment procedures: other relevant characteristics of the community/target 
population/environment have to be assessed (e.g. cognitions, attitudes, risk 
behaviours, criminality, social status, drug availability) 
 
P12 Assessment procedures: target population and community readiness for the 
service/intervention has to be assessed (e.g. sources of opposition or support) 
 
P13 Assessment procedures: gaps in current service provision have to be assessed 
 
P14 Stakeholder involvement: all stakeholders relevant to the service/intervention 
are involved in its development and implementation as required (e.g. target 
population, other agencies) 
 
P15 Sustainability: long-term strategy for drug prevention or wider health 
promotion (all activities form part of the long-term strategy) 
 
P16 Goal definition: service/intervention goals are specific, realistic and informed 
by assessment procedures (e.g. what types of drug use or behaviours are 
targeted) 
 
P17 Service/intervention design: the service/intervention is based on a scientifically 
derived understanding (theoretical models) of drug-related behaviours and 
behavioural change  
 
P18 Service/intervention design: the service/intervention is evidence-based (it is 
based upon the findings of novel or existing literature reviews on scientific 
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evidence of effectiveness, or professional experience where reviews are not 
available) 
 
P19 Service/intervention design: services/interventions are tailored according to 
individual and population characteristics (e.g. language, activities, messages, 
timing, number of participants) 
 
P20 Service/intervention design: criteria for end of the service/intervention are 
defined (e.g. goals achieved, mandatory number of sessions completed, number 
of participants reached, duration of the intervention) 
 
P21 Service/intervention design: service/intervention activities are feasible and 
internally consistent (e.g. activities are linked to objectives, target population is 
chosen in line with needs assessment, target population can be reached, setting 
is suitable for good functioning) 
 
P22 Adaptation: existing interventions (e.g. manualised programmes, service 
models implemented elsewhere) are adapted considering the differences 
between the original and the actual circumstances (e.g. target population 
characteristics) 
Exception: novel services/interventions 
 
P23 Staff training and development: those delivering the service/intervention (e.g. 
staff members, teachers, parents, former drug users) have the competencies 
which are required for a successful implementation  
 
P24 Recruitment: participants or participating units (e.g. schools, communities) are 
drawn from the defined target population 
 
P25 Implementation: a systematic project plan exists in writing (e.g. including main 
service/intervention elements and procedures, risk assessment and contingency 
plans) 
 
P26 Implementation: the implementation is monitored and necessary adjustments 
identified (e.g. reviewing preliminary outcome and process data, project plan, 
resources) 
 
P27 Implementation: the service/intervention is implemented according to the 
project plan and adjusted in line with the monitoring findings  
 
P28 Process evaluation: the implementation is documented and explained (failures 
and deviations from the original plan, target population involvement, activities, 
service/intervention delivery, use of financial, human, and material resources) 
 
P29 Dissemination: a written and clear description of the service/intervention is 
made (at least partly) available to relevant groups (e.g. participants) before 
and/or during the service/intervention 
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P30 Dissemination: information about the service/intervention is disseminated in an 
appropriate format (e.g. evidence briefings, report to funders, feedback to 
participants) at the end of the service/intervention 
 
Prevention: Outcome Standards at the System Level 
 
P31 Goal of prevention: reduced drug use (prevention must be aimed at abstention, 
delayed drug use, reduced drug use, and/or prevention of dependence) 
 
P32 Evaluation: an appropriate evaluation is carried out as part of the 
service/intervention (e.g. outcome evaluation, process evaluation) 
 
P33 Evaluation: the service/intervention is continued on the basis of evidence 
provided by monitoring or evaluation 
 
b. Treatment/rehabilitation standards 
  
Treatment/rehabilitation: Structural Standards of Services 
 
TR1 Accessibility: location (service can easily be reached by public transport)  
Added during conference 
Exception: prison-based services 
 
TR2 Physical environment (adequate spacing for the activities in the service (e.g. 
service has separate rooms for individual counselling) 
Added during conference 
Exception: non-specialised teams 
 
TR3 Physical environment: safety (service is equipped for emergencies like e.g. 
management of overdose, fire or aggression on the premises) 
Exception: non-specialised teams 
(as far as not already required by national law) 
 
TR4 Indication criteria: diagnosis (treatment indication is always made on  the basis 
of a diagnosis) 
Exception: office-based services and non-specialised teams 
 
TR5 Staff education: basic education (e.g. at least half of staff has a diploma in 
medicine, nursing, social work, or psychology) 
Exception: office-based and prison-based services, non-specialised teams 
 
TR6 Staff composition: transdisciplinarity (e.g. service employs a multidisciplinary 
team composed of at least 3 professions) 
Exception: prison-based services and non-specialised teams 
(country differences have to be taken into account) 
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Treatment/rehabilitation: Process Standards at the Service Level 
 
TRs7 Assessment procedures (substance use history, diagnosis and treatment history 
have to be assessed) 
Exception: office-based services and non-specialised teams 
 
TRs8 Assessment procedures (somatic status and social status have to be assessed) 
Exception:  office-based services and non-specialised teams 
 
TRs9 Assessment procedures (psychiatric status has to be assessed) 
 Added during conference 
Exception:  non-specialised teams 
 
TRs10 Individualised treatment planning: (treatment plans are tailored individually to 
the needs of the patient) 
Exception:  office-based and prison-based services,  non-specialised teams 
 
TRs11 Informed consent: (patients must receive information on available treatment 
options and agree with a proposed regime or plan or a change of plan before 
starting treatment)    
Exception: office-based and prison-based services, non-specialised teams 
 
TRs12 Written client records: (assessment results, intervention plan, interventions, 
expected changes and unexpected events are documented complete and up to 
date for each patient in a patient record) 
Exception: non-specialised teams 
 
TRs13 Confidentiality of client data: (patient records are confidential and exclusively 
accessible to staff involved in a patient’s treatment or regime) 
Exception: non-specialised teams 
 
TRs14 Routine cooperation with other agencies: (whenever a service is not equipped 
to deal with all needs of a given patient, an appropriate other service is at hand 
for referral) 
Exception: prison-based services and non-specialised teams 
 
TRs15 Continued staff training: (staff is regularly updated on relevant new knowledge 
in their field of action) 
Exception: non-specialised teams 
 
Comment: while these process standards are accepted for all interventions without 
exception, the same standards are not applicable in all types of services; exceptions 
are mentioned). 
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Treatment/rehabilitation: Process Standards of Interventions 
 
TRi7 Assessment procedures (substance use history, diagnosis and treatment history 
have to be assessed) 
 
TRi8 Assessment procedures (somatic status and social status have to be assessed) 
 
TRi9 Assessment procedures (psychiatric status has to be assessed) 
 
TRi10 Individualised treatment planning: (treatment plans are tailored individually to 
the needs of the patient) 
 
TRi11 Informed consent: (patients must receive information on available treatment 
options and agree with a proposed regime or plan or changes of plan before 
starting treatment) 
 
TRi12 Written client records: (assessment results, intervention plan, interventions, 
expected changes and unexpected events are documented complete and up to 
date for each patient in a patient record) 
 
TRi13 Confidentiality of client data: (patient records are confidential and exclusively 
accessible to staff involved in a patient’s treatment or regime) 
 
TRi14 Routine cooperation with other agencies: (whenever a service is not equipped 
to deal with all needs of a given patient, an appropriate other service is at hand 
to referral) 
 
TRi15 Continued staff training: (staff is regularly updated on relevant new knowledge 
in their field of action) 
 
Treatment/rehabilitation: Outcome Standards at the System Level 
 
TR16 Goal: health stabilisation/improvement (treatment must aim at improvements 
or stabilisation of health) 
Exception: non-specialised teams 
 
TR17 Goal: social stabilization/integration (treatment must aim at improvements of 
social stabilisation or integration) 
Exception: office-based and prison-based services, non-specialised teams 
 
TR18 Goal: reduced substance use (treatment must aim at a reduction of substance 
use e.g. helping the client/patient to reduce the use or to abstain from illegal or 
non-prescribed psychotropic substances) 
Exception: office-based services and non-specialised teams 
 
TR19 Utilisation monitoring: (services must report periodically the occupancy of 
treatment slots or beds) 
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Exception: office-based services and non-specialised teams 
 
TR20 Discharge monitoring: (e.g. ratio of regular / irregular discharges and retention 
rates have to be monitored periodically) 
Added during conference 
Exception: office-based and prison-based services, non specialised teams 
 
TR21 Internal evaluation: (services must regularly perform an internal evaluation of 
their activities and outcomes) 
Exception:  office-based and prison-based services, non-specialised teams 
 
TR22 External evaluation: (services must regularly allow an evaluation of their 
activities and outcomes by an independent external evaluator) 
Added during conference 
Exception: office based and prison based services, non specialised teams 
 
c. Harm reduction standards 
 
Harm Reduction: Structural Standards of Interventions  
 
HR1 Accessibility: location and opening hours (services have to match the needs of 
their clients; costs should never be a barrier to a service) 
 
HR2 Staff qualification: minimal qualification (staff has to be qualified and the staff 
qualification has to be made transparent, e.g. amongst two trained peers 
involved in the service, two have a diploma in social work and further two in 
nursing) 
Exception: needle-syringe exchange, outreach/street work, safer use and safer 
sex counselling, and sheltered housing 
 
HR3 Indication criteria: age limits (1. Services have to be age appropriate and staff 
has to be trained to meet age appropriate clients needs, 2. There should be no 
age limits in harm reduction services) 
 
Harm Reduction: Process Standards of Interventions  
 
HR4 Assessment procedures: risk behaviour assessment (client’s/patient’s risk 
behaviour is assessed) 
Exception: drug checking, BBV testing and counselling, vaccination, and 
sheltered housing 
 
HR5 Assessment procedures: complete needs assessment and priorisation (e.g. 1. 
Harm reduction of intravenous drug use and, 2. Reduction of used syringes in 
public spaces etc.) 
Added during conference 
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Exceptions: valid only for needle-syringe exchange, and supervised injection 
rooms 
 
HR6 Assessment procedures: client/patient status (the client’s/patient’s health status 
is assessed) 
Added during conference 
Exceptions: valid only for needle-syringe exchange, BBV testing and 
counselling, and vaccination 
 
HR7 Informed consent: (Clients/patients must receive information on available 
service options and agree with a proposed regime or plan before starting an 
intervention. Interventions should not be based on written informed consent, 
but rather on a transparently information about all the offers by a service.) 
Exception: needle-syringe exchange, outreach/street work, drug checking, 
safer use and safer sex counselling, and sheltered housing 
 
HR8 Confidentiality of client data: (client/patient records are confidential and 
exclusively accessible to staff involved in a client’s/patient’s intervention or 
regime) 
Exception: drug checking 
There was consensus at the conference that the standard on the confidentiality 
of client data should be intervention specific. Also, it was pointed that data 
should not be accessible without the agreement of the client and that the 
client’s needs should come first. 
 
HR9 Individualised treatment planning: (intervention regime and intervention plans, 
if applicable, are tailored individually to the needs of the client/patient) 
Added during conference 
High consensus for referrals   
 
HR10 Routine cooperation with other agencies: (whenever a service is not equipped 
to deal with all needs of a given client/patient, an appropriate other service is at 
hand for referral) 
Exception: drug checking 
 
HR11 Continued staff training: (staff is regularly updated on relevant new knowledge 
in their field of action) 
Exception: drug checking 
 
HR12 Neighbourhood/community consultation: (avoiding nuisance and conflict with 
other people around the service) 
Added during conference 
Exceptions: valid only for needle-syringe exchange, supervised injection 
rooms, and sheltered housing 
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Harm Reduction: Outcome Standards at the System Level 
 
HR13 Goal: reduced risk behaviour (reducing unsafe injections, unsafe drug use and 
unprotected sex) 
 
HR14 Goal: referrals (treatment services must be prepared to refer clients/patients to 
other health/social/treatment/legal services if needed and agreed) 
Exception: drug checking 
 
HR15 Internal evaluation: (services must regularly perform an internal evaluation of 
their activities and outcomes) 
Exception: drug checking 
 
HR16 External evaluation: (services must regularly allow an evaluation of their 
activities and outcomes by an independent external evaluator) 
Exception: drug checking, referrals, and sheltered housing 
For the standards on external evaluation, there was no consensus what it 
should include in the harm reduction context and thus, there should be at least 
a minimal definition. There was clearly non-consensus that external evaluation 
should not be obligatory based on written record keeping, and that external 
evaluation is often not feasibly due to insufficient funding.  
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7. Implementation of standards at national level 
 
The EQUS project collected systematic information on stakeholder views about the 
present state of implementation and the expected feasibility of implementation of the 
proposed minimum quality standards. This was part of the on-line surveys and of 
group discussions during the European conference. 
 
a. Data on acceptability of proposed standards 
 
The questionnaire for the stakeholder surveys included questions about the 
acceptability of the proposed quality standards. The following tables present the 
findings from the responses to the questionnaire.  
 
Prevention standards were not included in these stakeholder surveys; however, the 
findings of the equivalent survey and focus groups are available in the project report 
(Brotherhood et al., 2011).  
 
Table 6  Treatment/rehabilitation: acceptability of proposed quality standards 
 
Structural 
standards 
services 
 n Imple-
mented 
(%) 
Feasible 
no 
problems 
(%) 
Problems 
expected 
(%) 
Not 
feasible 
(%) 
No 
answer 
(%) 
TR1 Accessible 
location 
153 22 30 39 4 6 
TR2 Adequate space 149  40 28 24 1 7 
TR3 Safety provisions 150 27 19 33 9 11 
TR4 Diagnosis 
mandatory 
145 41 23 27 1 7 
TR5 Staff 
qualifications 
142 48 24 17 6 5 
TR6 Transdisciplinary 
staff 
143 26 21 41 8 4 
Process 
standards 
Services 
       
TRs7 Drug use assessed 84 44 38 12 1 5 
TRs8 Somatic status 
assessed 
84 36 39 16 2 7 
TRs9 Psych. status 
assessed 
84 24 32 32 4 8 
TRs10 Individual 
treatment plan 
84 38 23 29 4 7 
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TRs11 Informed consent 84 43 39 12 0 6 
TRs12 Written records 84 43 26 19 4 8 
TRs13 Data confidential 84 56 26 12 0 3 
TRs14 Routine 
cooperation 
84 25 26 36 6 7 
TRs15 Continued 
training staff 
84 30 24 41 0 6 
Process 
standards 
interventions 
       
TRi7 Drug use assessed 55 46 24 29 0 2 
TRi8 Somatic status 
assessed 
55 40 31 24 4 2 
TRi9 Psych. status 
assessed 
55 41 24 36 7 2 
TRi10 Individual 
treatment plan 
55 40 13 42 2 4 
TRi11 Informed consent 55 40 26 29 4 2 
TRi12 Written records 55 36 24 38 0 2 
TRi13 Data confidential 55 60 26 13 0 2 
TRi14 Routine 
cooperation 
55 29 18 49 2 2 
TRi15 Continued 
training staff 
55 31 16 46 6 2 
Outcome 
standards at 
system level 
       
TR16 Goal health 
improved 
142 42 29 22 1 6 
TR17 Goal social 
improved 
142 29 28 34 4 6 
TR18 Goal less 
substance use 
142 37 31 25 1 6 
TR19 Monitor 
utilisation 
142 30 30 29 3 8 
TR20 Monitor 
discharge 
142 15 25 40 12 9 
TR21 Internal 
evaluation 
142 23 25 39 9 5 
TR22 External 
evaluation 
141 8 16 53 17 6 
 Cost-
effectiveness 
140 4 11 51 22 11 
 Cost-benefit 139 2 9 42 32 15 
Note: Grey minimal quality standards without identification code were dropped from the minimal quality standard 
list after the online survey. 
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Table 7  Harm reduction: acceptability of proposed quality standards 
 
Structural 
standards 
interventions 
 n Imple-
mented 
(%) 
Feasible 
no 
problems 
(%) 
Problems 
expected 
(%) 
Not 
feasible 
(%) 
No 
answer 
(%) 
HR1 Accessible location 147 17 23 45 10 5 
HR1 Opening hours 140 16 24 44 14 1 
HR1 Low costs for 
patients 
138 23 18 26 22 11 
HR2 Staff qualifications 133 35 27 23 11 5 
HR3 Age limits 135 22 21 29 16 13 
 Transdisciplinary 
staff 
133 17 20 34 24 5 
 Diagnosis mandatory 137 29 22 23 17 9 
Process 
standards 
interventions 
       
HR4 Risk behavior 
assessed 
125 24 35 25 10 6 
HR5 Indiv. needs 
assessment 
127 14 32 28 13 13 
HR6 Client status assessed 126 21 33 26 11 10 
HR7 Informed consent 124 40 28 20 7 5 
HR8 Data confidential 124 56 27 12 2 3 
HR9 Individual treatment 
plan 
125 20 26 33 17 5 
HR10 Routine cooperation 124 35 20 40 4 2 
HR11 Continued staff 
training  
123 25 28 42 5 1 
HR12 Neighbourhood 
consult. 
123 23 23 33 15 7 
 Written records 124 21 26 26 19 8 
Outcome 
standards at 
system level 
       
HR13 Goal less risk 
behavior 
133 40 19 35 4 2 
HR14 Goal referrals if 
needed 
130 42 19 31 5 2 
HR15 Internal evaluation 130 24 29 37 8 2 
HR16 External evaluation 129 9 16 54 16 5 
 Goal less substance 
use 
131 24 21 34 14 8 
 Monitor utilisation 130 29 31 25 9 6 
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 Cost-effectiveness 129 5 16 40 26 12 
 Cost-benefit 128 2 17 38 31 13 
Note: HR1: These three standards were integrated into one but assessed separately in the online survey. Grey 
minimal quality standards without identification code were dropped from the minimal quality standard list after the 
online survey. 
 
Are the status of standard implementation and the expected feasibility to implement 
them equally distributed among the European Union ? The following tables show the 
distribution across three regions (South-West includes Austria, Belgium, Cyprus, 
France, Germany, Greece, Italy, Netherlands, Portugal, Spain, Switzerland; Central-
East includes Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, 
Romania, Slovakia, Slovenia; North includes Denmark, Finland, Ireland, Sweden, 
United Kingdom).   
  
Table 8  Implementation status of treatment/rehabilitation standards 
 
Code  Already implemented 
(% within region) 
Feasible without 
problems 
(% within region) 
Problems expected 
(% within region) 
Not feasible 
(% within region) 
 South
- 
West 
Centr
al-
East 
North South 
- 
West 
Centr
al-
East 
North South
- 
West 
Centr
al-
East 
North South
- 
West 
Centr
al-
East 
North 
TR1 23 19 22 27 30 39 37 42 35 4 5 0 
TR2 46 34 35 20 34 39 24 25 17 0 4 0 
TR3 23 32 26 21 18 17 31 32 44 11 9 4 
TR4 37 55 23 22 22 32 31 18 36 10 4 0 
TR5 55 50 23 24 26 18 8 19 41 5 6 14 
TR6 30 29 5 23 18 23 32 49 20 8 4 18 
TRs7 38 54 46 38 31 54 13 15 0 2 0 0 
TRs8 31 39 46 47 35 23 11 23 15 2 4 0 
TRs9 16 35 31 38 27 23 33 35 23 2 4 8 
TRs10 33 46 39 24 15 31 39 35 15 4 4 0 
TRs11 33 62 39 42 35 39 16 4 15 0 0 0 
TRs12 31 58 54 29 27 15 24 8 23 0 8 0 
TRs13 51 65 54 29 23 23 11 12 15 0 0 0 
TRs14 20 27 39 33 15 23 31 46 31 7 8 0 
TRs15 29 35 23 24 19 31 38 46 39 0 0 0 
TRi7 60 41 25 10 33 25 25 26 50 0 0 0 
TRi8 45 37 38 30 37 13 15 22 50 5 4 0 
TRi9 35 37 0 20 30 16 40 33 38 0 0 50 
TRi10 45 41 25 5 22 0 40 33 75 5 0 0 
TRi11 35 41 50 20 33 13 35 22 38 5 4 0 
TRi12 45 37 13 10 33 25 40 30 63 0 0 0 
TRi13 70 48 75 20 37 0 5 15 25 0 0 0 
TRi14 35 30 13 15 26 0 45 41 88 0 4 0 
TRi15 30 37 13 20 19 0 35 44 75 10 0 13 
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TR16 44 43 32 27 33 23 18 20 36 2 2 0 
TR17 35 28 14 27 26 32 29 35 46 2 9 0 
TR18 38 41 27 32 32 27 20 24 41 2 2 0 
TR19 30 35 18 27 32 36 24 32 36 3 2 5 
TR20 12 11 32 29 22 18 38 41 46 10 19 0 
TR21 23 28 14 23 26 27 42 33 41 3 11 18 
TR22 8 9 5 17 15 14 52 48 71 15 22 10 
 
 
Table 9  Implementation status of harm reduction standards 
 
Code  Already implemented 
(% within region) 
Feasible without 
problems  
(% within region) 
Problems expected 
(% within region) 
Not feasible 
(% within region) 
 South
- 
West 
Centr
al-
East 
North South
- 
West 
Centr
al-
East 
North South
- 
West 
Centr
al-
East 
North South
- 
West 
Centr
al-
East 
North 
HR1 21 16 10 24 24 21 40 47 52 8 14 10 
HR1 21 14 11 26 29 11 39 39 63 11 18 15 
HR1 27 14 30 18 20 15 21 38 15 26 16 31 
HR2 52 19 26 27 31 17 16 29 26 2 15 26 
HR3 23 20 21 23 22 13 27 22 46 13 18 17 
HR4 23 16 43 42 36 14 22 30 24 7 16 10 
HR5 17 9 18 43 22 18 25 31 32 5 24 14 
HR6 23 9 36 42 27 18 23 27 32 3 23 9 
HR7 44 32 43 22 34 33 22 18 19 5 14 0 
HR8 61 52 48 27 39 5 5 9 38 2 0 5 
HR9 20 14 33 32 23 14 27 36 43 13 25 10 
HR10 37 25 48 20 23 14 39 46 29 2 7 5 
HR11 29 21 24 35 23 19 29 50 57 5 7 0 
HR12 29 9 33 29 18 14 31 30 43 5 32 5 
HR13 57 19 39 15 27 13 23 48 44 3 4 4 
HR14 52 24 52 19 22 13 19 44 35 5 9 0 
HR15 31 16 22 27 33 26 32 40 44 7 11 4 
HR16 11 4 9 13 20 18 57 49 59 13 24 9 
 
61 
 
b. Data on expected implementation problems 
In the stakeholder survey questionnaire, the answer option for expected problems for 
an implementation of the proposed minimum quality standards had to be specified on 
a separate page. The results of these specifications are presented in the following 
tables. 
 
Table 10 Treatment / rehabilitation: expected problems for implementation 
 
Structural 
standards 
services 
 n Political 
pro-
blems 
(%) 
Professio-
nal 
Pro-
blems 
(%) 
Legal 
pro-
blems 
(%) 
Finan-
cial 
pro-
blems 
(%) 
Ethical 
pro-
blems 
(%) 
Other 
pro-
blems  
(%) 
TR1 Accessible location 25 16 16 14 34 4 16 
TR2 Adequate space 17 12 8 4 52 8 16 
TR3 Safety provisions 17 13 16 10 42 10 10 
TR4 Diagnosis 
mandatory 
16 12 32 4 32 4 16 
TR5 Staff qualifications 11 6 25 0 50 0 19 
TR6 Transdisciplinary 
staff 
25 9 23 6 53 0 9 
Process 
standards 
services 
        
TRs7 Drug use assessed 13 4 21 11 29 18 18 
TRs8 Somatic status 
assessed 
27 5 27 5 50 5 9 
TRs9 Psych. status 
assessed 
24 4 29 2 39 8 18 
TRs10 Individual treatment 
plan 
10 6 33 3 39 0 19 
TRs11 Informed consent 16 13 31 6 13 13 25 
TRs12 Written records 10 0 17 4 30 0 30 
TRs13 Data confidential 30 7 7 21 7 7 50 
TRs14 Routine cooperation 33 2 26 13 23 9 26 
TRs15 Continued staff 
training 
16 2 17 0 67 0 15 
Process 
standards 
intervene-
tions 
        
TRi7 Drug use assessed 16 7 29 0 43 11 11 
TRi8 Somatic status 
assessed 
13 5 27 9 46 5 9 
TRi9 Psych. status 20 0 34 6 43 6 11 
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assessed 
TRi10 Individual treatment 
plan 
23 5 30 5 45 3 13 
TRi11 Informed consent 16 13 32 8 24 11 13 
TRi12 Written records 21 0 31 6 34 6 23 
TRi13 Data confidential 7 0 22 11 22 0 44 
TRi14 Routine cooperation 27 9 33 7 38 2 11 
TRi15 Continued staff 
training 
25 0 23 3 71 0 3 
Outcome 
standards 
at system 
level 
        
TR16 Goal health 
improvement 
17 22 19 11 24 8 16 
TR17 Goal social 
improvement 
21 14 20 10 37 2 18 
TR18 Goal less substance 
use 
17 16 23 10 26 10 16 
TR19 Monitor utilisation 17 4 28 4 36 12 16 
TR20 Monitor discharge 22 2 39 15 27 7 10 
TR21 Internal evaluation 21 3 43 3 30 5 18 
TR22 External evaluation 30 5 29 11 38 6 11 
 Cost-effectiveness 31 12 30 6 32 10 10 
 Cost-benefit 23 14 29 6 33 10 8 
Note: Grey minimal quality standards without identification code were dropped from the minimal quality standard 
list after the online survey. 
 
Table 11 Harm reduction: expected problems for implementation 
 
Structural 
standards 
interventions 
 n Political 
pro-
blems 
(%) 
Professio-
nal 
problems 
(%) 
Legal 
pro-
blems 
(%) 
Finan-
cial pro-
blems 
(%) 
Ethical 
pro-
blems 
(%) 
Other 
pro-
blems  
(%) 
HR1 Accessible location 66 23 12 15 31 5 14 
HR1 Opening hours 61 14 18 9 48 3 9 
HR1 Low costs for 
patients 
37 24 8 11 35 10 12 
HR2 Staff qualifications 31 4 10 12 51 2 20 
HR3 Age limits 39 17 15 24 6 27 11 
 Transdisciplinary 
staff 
45 5 24 4 50 1 15 
 Diagnosis 
mandatory 
32 14 19 7 33 7 19 
Process 
standards 
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interventions 
HR4 Risk behavior 
assessed 
31 4 21 4 31 13 27 
HR5 Indiv. needs 
assessment 
36 17 15 8 40 5 15 
HR6 Client status 
assessed 
32 7 22 2 40 9 20 
HR7 Informed consent 25 8 36 13 15 8 21 
HR8 Data confidential 15 9 18 9 9 14 41 
HR9 Individual treatment 
plan 
42 8 20 5 37 8 22 
HR10 Routine cooperation 49 7 32 10 28 5 17 
HR11 Continued staff 
training 
52 5 12 1 66 1 15 
HR12 Neighbourhood 
consult. 
42 27 21 11 16 11 15 
 Written records 32 2 26 17 24 10 21 
Outcome 
standards at 
system level 
        
HR13 Goal less risk 
behavior 
47 20 16 12 30 11 11 
HR14 Goal referrals if 
needed 
40 6 26 11 32 3 22 
HR15 Internal evaluation 49 4 24 4 40 3 25 
HR16 External evaluation 70 9 27 3 45 3 14 
 Goal less substance 
use 
44 9 21 11 19 16 24 
 Monitor utilisation 33 4 26 9 30 8 23 
 Cost-effectiveness 52 11 19 5 29 8 28 
 Cost-benefit 48 17 14 4 30 4 32 
Note: Grey minimal quality standards without identification code were dropped from the minimal quality standard 
list after the online survey. 
 
These findings show that: 
 
- the rate of already implemented standards and of expected implementation 
without problems exceeds the number of expected problems for most standards 
in treatment/rehabilitation services and interventions, with the exception of 
three outcome standards (external evaluation, cost-effectiveness and cost-
benefit analysis) 
- for harm reduction interventions, the rate of expected implementation problems 
exceeds the rate of implementation and expected implementation without 
problems, even in the countries where harm reduction measures have been 
introduced  
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- the rate of standards for which an implementation is considered not to be 
feasible, is very low in treatment/rehabilitation (with the exception of the 
outcome standards mentioned above), but higher in harm reduction 
- among the expected problems for implementation prevail the concerns about 
acceptance by professionals and the financial costs of implementation 
- comparatively few problems are expected from political, legal and ethical 
concerns. 
 
More information would be needed for identifying the practical consequences of 
standard implementation. This is the case for some of the structural standards of 
services; e.g. insufficient accessibility could lead to finding a new and better suited 
location for a given service, or insufficient space for confidential client assessment and 
counselling may result in reallocating rooms for other functions. For other standards, 
the national conditions must be considered, e.g. the education and training of the 
various professionals involved in services for substance abuse treatment and harm 
reduction is relevant for the standards on qualifications and  transdisciplinarity of staff. 
Such implementation problems need to be handled at the national or local level. 
 
c. Lessons from models of implementation 
 
Four different national approaches introduced in NL, Czech Republic, UK and CH to 
implement standards to improve the quality of drug services were presented at the 
conference: The Czech accreditation process, the outputs of drug treatment in the UK, 
the Dutch guidelines on the treatment of drug and alcohol abuse and the Swiss system 
of incentives for promoting quality norms for drug treatment services22.  
 
While national approaches differ, the presentations all addressed the role of incentives 
as a key part of any strategy to implement quality standards in drug demand reduction: 
promotion via conferences/working groups/manual, training of practitioners, 
stakeholder participation and a certification and oversight system.   
 
At the EU level, the development and adoption of the European cancer screening 
guidelines provided a thought provoking example of how to introduce standards in the 
healthcare field. The key pre-requisites include the involvement of civil society, good 
governance (long-term political commitment, adequate/sustainable resources and 
oversight of standard implementation), effective programme management and 
international collaboration.  
                                                 
22 For details see presentations ion conference website http://ec.europa.eu/justice/newsroom/anti-
drugs/events/110615_en.htm 
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8. Ideas for further research and follow-up projects 
 
a. Missing Information: a gap analysis 
 
Further research should take into consideration the information gaps which were 
identified during the project.  
 
One major gap concerns the type of quality standards. It must be remembered here that 
quality standards are intended to be useful for different target audiences: intervention 
standards are of greatest interest for professionals performing interventions, while 
service standards are most relevant for service directors and managers, and system 
standards for health authorities, planners and policy makers. It would make sense to 
involve all these different audiences in a process to identify priority needs for 
standards which are not sufficiently represented in the lists resulting from the EQUS 
project. Such a needs assessment would be the appropriate methodology to find 
concrete proposals for a future research agenda.   
 
In the inventory, we see a lack of legal and ethical standards, coverage standards and 
economic standards (in terms of cost-benefit ratio, cost-effectiveness ratio and cost-
utilisation ratio). All these are priority items in a health policy perspective.  
 
There is an uneven situation in regard to ethical and legal standards. The inventory of 
prevention standards includes standards on legal and ethical adequacy. Also, the 
EQUS treatment/rehabilitation and harm reduction standards include some ethical 
standards as process quality standards - on informed consent (T11/19, HR5) and 
confidentiality of client data (T13/21, HR6). A comprehensive list of ethical standards 
in terms of structural quality standards would include items of professional 
competence and conduct in general, rights and obligations of patients and staff, 
transparency of such rights and obligations,  responsibility of services and information 
towards the general public 23. 
 
Proposals for the respective legal standards have to be checked on the basis of 
international and national legislation, on national documents on accreditation norms 
for services and specific interventions, and a consensus process will be needed for 
identifying shared minimum standards. Particularly in regard to non-clinical 
interventions, further legal guidance (‘research governance’) is needed. Although 
some legal standards are available (e.g. on compliance with health and safety laws, 
child protection, financial requirements etc.), there is a lack of prescriptive legal 
standards specifying what non-clinical interventions and procedures are acceptable. 
Such standards are available for clinical interventions (e.g. governing administration 
of methadone), but not for psychosocial interventions (including prevention).  
 
                                                 
23 A provisional list of ethical aspects in the treatment and care of drug users was set up in the 
framework of a project by WHO (WHO 2002a) 
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Benchmarks of coverage and cost-related outcomes must be based on generally 
accepted methodology and an expert consensus on minimum values acceptable as 
benchmarks. As the literature search performed for establishing the inventories did not 
result in relevant documents for these standards, new research to fill the gaps is 
recommended (see marked fields below). 24 
 
Table 12 Areas without available standards (in red) or insufficient availability (in green) 
 
 Level 1: 
interventions 
Level 2: services Level 3: systems & 
policies 
Structural 
quality 
Type of setting needed 
for implementation   
Resource standards 
(infrastructure, 
human resources)  
Legal & ethical 
adequacy standards 
(adequate to legal & 
ethical national norms) 
Process 
quality 
Implementation 
standards 
Procedural standards Standards for 
networking & 
cooperation among 
services 
Outcome 
quality 
Efficacy standards 
(having the intended 
effect) 
Effectiveness 
standards (reaching 
useful results) 
Coverage standards 
(proportion of those in 
need who are covered) 
 Economic 
outcome 
quality 
Cost-benefit ratio 
(economic benefits in 
relation to costs) 
Cost-utilization ratio 
(coverage in relation 
to costs) 
Cost-effectiveness ratio 
(positive results in 
relation to costs) 
 
 
Another gap exists in terms of available evidence for the proposed quality standards. 
As can be seen from the following tables, there is a major deficit of documents which 
provide grades of evidence for specific standards; most standards are based on expert 
opinion and expert consensus or on literature reviews without having an evidence base 
(this is also the case for prevention).  A future research agenda could be based on a 
priority list of standards for which appropriate evidence should be available (Grade A 
and B are the ‘gold standard’ for therapeutic interventions and therefore especially 
relevant here for interventions and process standards, while grade C is relevant for the 
effectiveness in ‘real world’ settings and for economic standards).  
 
Table 13 Which evidence is appropriate for which type of standard? 
 
Grade Definition 
A Highest degree of evidence: review from multiple randomised controlled 
studies (RTC) with convergent results 
                                                 
24 Materials and instruments for economic evaluations have been collected in the framework of a project 
by WHO (WHO 2002b)   
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Relevant for comparing interventions and procedural standards 
B High degree of evidence; results from single RCT and controlled clinical 
studies 
Relevant for comparing interventions and procedural standards 
C Moderate degree of evidence: prospective comparative longitudinal studies 
(observational studies without control design) 
Relevant for effectiveness and economic outcome standards 
D Low degree of evidence: single intervention/service follow-up studies, case 
studies 
Relevant for some structural standards 
E Very low degree of evidence: non-systematic observations 
Z Not known. 
 
This seems especially important in the case of minimum standards for which no 
evidence grade A or B is available so far and for which an experimental testing 
through randomised controlled studies is feasible and useful. Testing is more relevant 
for intervention standards, while observational studies (grade C) can be more relevant 
for service and system standards.  Expert consensus is the best guidance if no research 
evidence is available or feasible. Priorities must also be identified from the 
practitioners side; for some standards, more evidence would be welcome (e.g. staff 
education and transdisciplinarity), for others it seems less urgent (e.g. safety issues). 
About the level of education and transdisciplinarity of staff, the participants to the 
conference of Bruxelles (15-17 June 2011) clearly noted that as the education system 
for the non-medical professions is varied across Europe, some flexibility for 
adaptation should be left. 
 
 
Table 14 Accepted treatment and rehabilitation minimal quality standards: evidence 
  grading and source of evidence 
 
 Number of Documents / 
Evidence Grade 
Source of Document 
 
 
 
 
Structural standards of 
services 
A B C D E Lit. 
Re-
view 
Exp. 
Opi-
nion 
Exp. 
Con-
sen-
sus 
Re-
sear
ch 
pro-
ject 
Prac-
tice 
exper
ience 
TR1 Accessibility: location 0 0 1 4 6 22 28 31 14 26 
TR2 Physical environment: 
space 
0 1 0 5 4 19 32 39 6 32 
TR3 Physical environment: 
safety 
0 1 3 3 4 28 29 45 12 40 
TR4 Indication criteria: 
diagnosis 
5 1 8 4 11 49 58 74 22 54 
TR 5 Staff composition: level 1 0 3 4 14 44 62 76 25 60 
68 
 
of education 
TR 6 Staff composition: 
transdisciplinarity 
0 1 3 2 11 38 52 63 19 51 
           
Process standards at the 
service level 
          
TRs7 Assessment procedures: 
substance use history, diagnosis 
and treatment history 
13 3 21 36 37 78 89 105 40 78 
TRs8 Assessment procedures: 
somatic status and social status 
5 2 9 21 30 65 78 89 39 63 
TRs9 Assessment procedures: 
psychiatric status 
2 2 8 11 15 63 74 85 36 64 
TRs10 Individualised treatment 
planning 
4 6 7 15 15 83 98 116 46 86 
TRs11 Informed consent 3 1 7 12 3 68 80 93 36 71 
TRs12 Written client records 1 0 8 4 6 65 75 92 32 68 
TRs13 Confidentiality of client 
data 
2 1 5 10 3 60 75 83 34 64 
TRs14 Routine cooperation 
with other agencies 
1 2 6 15 10 62 85 102 30 74 
TRs15 Continued staff training 3 0 3 12 8 55 74 86 31 64 
Process standards of 
interventions 
          
TRi7 Assessment procedures: 
substance use history, diagnosis 
and treatment history 
13 3 21 36 37 78 89 105 40 78 
TRi8 Assessment procedures: 
somatic status and social status 
5 2 9 21 30 65 78 89 39 63 
TRi9 Assessment procedures: 
psychiatric status 
2 2 8 11 15 63 74 85 36 64 
TRi10 Individualised treatment 
planning 
4 6 7 15 15 83 98 116 46 86 
TRi11 Informed consent 3 1 7 12 3 68 80 93 36 71 
TRi12 Written client records 1 0 8 4 6 65 75 92 32 68 
TRi13 Confidentiality of client 
data 
2 1 5 10 3 60 75 83 34 64 
TRi14 Routine cooperation 
with other agencies 
1 2 6 15 10 62 85 102 30 74 
TRi15 Continued staff training 3 0 3 12 8 55 74 86 31 64 
Outcome standards at the 
system level 
          
TR16 Goal of treatment: health 
stabilisation/improvement 
2 0 9 5 4 66 77 93 31 58 
TR17 Goal of treatment: social 
stabilization/integration 
1 0 3 4 14 53 66 89 28 53 
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TR18 Goal of treatment: 
reduced substance use 
4 2 9 5 8 62 78 93 37 65 
TR19 Utilisation monitoring 0 2 2 4 0 18 33 37 15 29 
TR20 Discharge monitoring 0 0 1 3 0 13 31 33 10 26 
TR21 Internal Evaluation 2 0 4 6 6 27 46 55 18 41 
TR22 External Evaluation 0 0 2 7 0 18 36 39 14 32 
 
It is not surprising that there is less evidence for harm reduction standards, for a 
number of reasons. Harm reduction interventions and services have been developed 
later and less frequently than treatment and rehabilitation, and research concentrated 
more on collecting observational data than on experimental designs. Expert opinion 
and consensus play a major role.  
Also, research has focused more on evidence for the effectiveness of harm reduction 
approaches for specific objectives (e.g. prevention of blood borne infections or 
overdose death) than on the role of quality standards to be observed in specific 
intervention types or services. Evidence for the effectiveness of harm reduction 
approaches has been carefully reviewed and the main knowledge gaps in this field 
have been identified (see Rhodes & Hedrich 2010). However, this type of evidence 
was not the focus in the EQUS project. The question was not if recommendations can 
be made for the availability of an intervention or service, based on relevant evidence, 
but which quality standards should be observed if a specific approach is made 
available. The tables below document the present state of evidence and lack of 
evidence in regard to such standards, as a starting point of a future research agenda.    
 
Table 15 Accepted harm reduction minimal quality standards: evidence grading & source 
  of evidence  
 
 
Number of Documents / 
Evidence Grade 
Source of Document 
 
 
 
 
Structural standards interventions 
A B C D E Lit. 
Re-
view
Exp. 
Opi-
nion 
Exp. 
Con-
sen-
sus 
Re-
searc
h 
pro-
ject 
Prac-
tice 
expe
rienc
e 
HR1 Accessibility: services have to 
match the needs of their clients 
          
costs 0 0 1 0 0 7 7 3 4 10 
location  0 0 2 2 1 11 10 8 11 17 
opening hours 0 0 2 2 2 12 12 9 7 13 
HR2 Staff qualification: minimal 
qualification 
0 0 1 2 1 12 17 12 10 22 
HR3 Indication criteria: age limits 0 0 0 5 3 9 13 11 3 11 
Process standards interventions           
HR4 Assessment procedures: risk 
behaviour assessment 
0 0 2 1 1 15 12 8 9 15 
HR5 Assessment procedures: 0 0 2 3 2 9 11 9 8 13 
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complete needs assessment and 
priorisation 
HR6 Assessment procedures: 
client/patient status 
0 0 2 5 3 16 17 14 10 16 
HR7 Informed consent 0 0 2 5 1 12 13 14 6 11 
HR8 Confidentiality of client data 0 0 3 6 1 18 17 17 10 19 
HR9 Individualised treatment 
planning 
0 0 1 2 0 13 15 10 9 16 
HR10 Routine cooperation with other 
agencies 
0 0 3 9 1 22 23 22 15 22 
HR11 Continued staff training 1 0 2 3 0 17 18 15 8 20 
HR12 Neighbourhood/community 
consultation 
0 0 2 1 1 9 12 10 7 8 
Outcome standards at system level           
HR13 Goal: reduced risk behaviour 2 0 4 7 1 25 25 25 15 26 
HR14 Goal: referrals 1 0 3 3 1 17 19 16 11 20 
HR15 Internal Evaluation 1 0 0 0 0 9 15 12 8 11 
HR16 External Evaluation 1 0 1 1 0 11 17 13 9 11 
 
 
Finally, the present lists of minimum standards are not definite. It can be expected that 
additional standards will be proposed, e.g on the continuity of care (including aftercare 
for released prison inmates) or on specific assessment methods (urine screening for 
psychotropic substances). Especially controversial standards are of interest here, as 
they would need clarification and guidance.  
 
Furthermore it must be mentioned, that if new research contributes to better and 
updated information, a revision of the lists is inevitable. It is recommended to set up 
plans, when and how a revision should be made. 
 
In conclusion, the findings from the gap analysis provide an opportunity to formulate 
some implications for the future research agenda in the area of quality standards for 
treatment/rehabilitation and harm reduction: 
 
- Standards have a different value, although not exclusively, for different target 
audiences; intervention standards are of greatest interest for professionals 
performing interventions, while service standards are most relevant for service 
directors and managers, and system standards for health authorities, planners 
and policy makers. It is therefore highly recommendable to assess and 
consider the priority needs of these audiences when setting up a research 
agenda, in regard to deficient evidence for proposed standards as well as to 
additional standards not included in the proposed lists 
- New research on quality standards must consider the most appropriate 
methodology per type of standard    
- New research on quality standards must consider the degree of documented 
acceptability of the proposed quality standards; the more controversial 
71 
 
standards should have a priority over the well accepted and non-disputed 
standards 
- In view of the present trend towards an improved quality of action at the 
system level, a priority is recommended for research on economic and 
coverage standards and for the development of the methodologies for such 
studies. 
 
b.   Proposal for an EU consensus on minimum quality standards 
 
The list of proposed minimum quality standards are recommendations addressed to the 
European Commission to underpin its work on a proposal for an EU consensus on 
minimum quality standards, now planned for 2013.  
 
European level minimum quality standards will need  to add value to what exists in the 
EU member states and take account of different health systems and capacities across 
Member States.   
 
Political choices still have to be made and further research carried out to strengthen 
available the evidence base as described in the gap analysis.  
 
It is highly recommended to continue the consensus building process with 
stakeholders, in parallel to the political decision-making process,  to promote a 
common understanding of the need and objectives of the proposed quality standards in 
the field of drug demand reduction. 
 
As an incentive and to encourage the consensus building process at national and EU 
level, the European Commission has confirmed that will propose EU funding  for such 
initiatives under its Drug Prevention and Information Programme 2012 as well as 
funding for further research to support the evidence base of the quality standards. 
 
c. Proposals for an extended consensus building process 
 
Based on the outcomes of the consensus building process, options for concrete steps 
and procedures are proposed for further action. They focus is on the dissemination and 
implementation of the proposed lists of minimum quality standards. The options are: 
 
- Editing of the proposed lists of minimal quality standards with a short 
commentary and glossary as a manual25. This would greatly facilitate the 
practical implementation of the standards and the adaptation to the diverse 
national situations  
                                                 
25 The European drug prevention quality standards, upon which the EQUS prevention standards are 
based, are published and available on the internet as EMCDDA Manual No 7 (EMCDDA, 2011); 
translated versions of the manual (e.g. Italian, Hungarian, Polish) are planned. Manualisation of the 
EQUS standards may take a similar approach. 
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- Access to the manual via internet, including a platform for the interactive 
exchange on implementation experiences 
- Translation of the manual into national languages (plus internet access) 
- National meetings / conferences for discussing the manual and the models 
of implementation, starting in pilot countries (e.g. Spain, Finland, Czech 
Republic) 
- Regional meetings / conferences for an exchange of implementation 
experience 
- Integration of workshops on the use of the manual into professional 
national and international conferences 
- Support of such meetings and workshops by European Commission and 
EMCDDA, though technical assistance and incentives 
- Assistance by EMCDDA to national authorities for monitoring their 
implementation activities 
- Monitoring the implementation process   
- Access to monitoring results via internet.  
 
c. Moving from proposed lists to international implementation guidelines 
 
Implementation of standards in everyday practice, not only in theory, profits from 
detailed guidelines about how to use and respect the standards, including guidance for 
exceptions and recommendations for training. Such guidelines are more 
comprehensive in comparison to a manual; they also indicate the evidence base for the 
recommendations. There is an interest for developing such guidelines, especially for 
low- and middle-income countries, also outside of the European region. 
 
The results of the project have significant potential for developing and implementing 
minimum quality standards at a larger international scale, which may have a serious 
impact on coverage and quality of prevention and treatment interventions and services 
worldwide. Setting norms and standards for the global health is one of the core 
functions of the World Health Organization (WHO), and WHO would be the natural 
partner in further developments of the standards, following WHO procedures, and 
their adoption and implementation in different parts of the world. The EQUS project 
provides a strong basis for engaging the collaboration with WHO, the global quality 
standards and support their implementation in other parts of the world. 
 
In the area of prevention, follow-up work is currently being prepared which will seek 
to develop detailed guidance and training in relation to the quality standards for policy 
makers and practitioners in Europe. Moreover, efforts are also underway to develop 
international prevention standards and guidelines which will build upon the EQUS 
prevention standards and other major developments in the field. 
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d. Monitoring and evaluating the implementation process. 
 
The political decisions about implementation have yet to be taken. Based on this 
decision the Commission should decide how to monitor the process. The EMCDDA - 
in the framework of it’s mandate - should support the monitoring activities process 
and evaluation. However, it is recommendable to set up a concept paper and working 
plan for monitoring the implementation process in Member States, in order to learn 
from positive and problematic experience and to provide feedback to interested 
parties. 
 
Finally, an independent evaluation of the process and the outcome of implementation 
efforts can provide insight and lessons for comparable project. 
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